var title_f18_4_18496="Hiatal hernia after gastric sleeve";
var content_f18_4_18496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hiatal hernia after gastric sleeve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a patient with a hiatal hernia, an UGI series will show the GE junction above the diagphragm as shown here. The upper arrow shows the hiatal hernia and the lower arrow shows the dilated sleeve gastrectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18496=[""].join("\n");
var outline_f18_4_18496=null;
var title_f18_4_18497="Push through method";
var content_f18_4_18497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Push-through method of fish-hook removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 495px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. Anesthetize the skin adjacent to the hook. B. Push the hook forward until the barb comes back through the skin. C. With eye protection in place, clip the barb of the hook with wirecutters. D. Back the remaining portion of the hook out of the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Diekema DS. Fishhook removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18497=[""].join("\n");
var outline_f18_4_18497=null;
var title_f18_4_18498="Ultrasound pyloric stenosis";
var content_f18_4_18498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyloric stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image showing the thickened pyloric muscle of pyloric stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary L Brandt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18498=[""].join("\n");
var outline_f18_4_18498=null;
var title_f18_4_18499="Absorbable gelatin: Drug information";
var content_f18_4_18499=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Absorbable gelatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gelfilm&reg;;",
"     </li>",
"     <li>",
"      Gelfoam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hemostatic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemostasis (Gelfoam&reg;):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Use minimum amount of product necessary to produce hemostasis; once hemostasis attained, excess product should be removed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dental sponge: Insert rolled sponge (dry or wet) into cavity or socket; apply light finger pressure for 1-2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sponge: Apply appropriate size (dry or wet) with moderate pressure directly to bleeding site until bleeding stops; if first application does not stop bleeding, additional applications may be used with a new sponge",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Powder: Apply paste to bleeding surface; remove excess paste when bleeding has stopped. Consult manufacturer&rsquo;s labeling for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neurosurgery, thoracic, or ocular surgery (Gelfilm&reg;):",
"     </b>",
"     Use as directed per manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F175515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F175514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Film, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfilm&reg;:  (6s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Film, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfilm&reg;:  (1s) [100 mm x 125 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfoam&reg;:  (1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge, oral topical [dental]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfoam&reg;:  (12s) [Size 4]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfoam&reg;:  (6s) [Compressed-Size 100]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfoam&reg;:  (6s) [Size 100]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfoam&reg;:  (12s) [Size 12-7 mm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfoam&reg;:  (6s) [Size 200]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelfoam&reg;:  (4s) [Size 50]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13909140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sterile technique should be used when removing product from package.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sponge (Gelfoam&reg;): Cut sponge to required size; dry or wet sponge may be applied to bleeding site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dry sponge: Manually compress dry sponge prior to application to bleeding site; hold in place with moderate pressure until bleeding stops",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Wet sponge: Immerse sponge in sterile saline, remove from solution, squeeze between gloved fingers to remove air bubbles, and return to saline solution until needed. Sponge should return to original size after air is expelled. Wet sponge may be blotted to dampness on gauze prior to application and may be held in place with a small gauze sponge until bleeding stops. Remove gauze from sponge by wetting with a few drops of sterile saline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder (Gelfoam&reg;): Prepare a puttylike paste by placing the powder into sterile beaker and adding ~3-4 mL of sterile saline.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to provide hemostasis in surgical procedures; adjunct in neuro, thoracic, or   ocular surgeries to promote tissue repair and/or prevent adhesions (Gelfilm&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Abscess and infection formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Foreign body reactions, encapsulation of fluid and hematoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse events reported when used in various surgical procedures (Gelfoam&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Cardiopulmonary bypass surgery:",
"     </i>",
"     Atrial fibrillation (13%), wound infection (6%), heart failure (4%), atrial flutter (2%), peripheral vascular disorder (2%), pneumothorax (2%), respiratory arrest (2%), respiratory failure (2%), ventricular tachycardia (2%), fever (1%), heart block (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Implant in brain:",
"     </i>",
"     Compression of brain and spinal cord, giant-cell granuloma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Laminectomy operations:",
"     </i>",
"     Arachnoiditis, bladder and bowel dysfunction, cauda equine syndrome, headaches, impotence, meningitis, pain, paresthesias, spinal stenosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Nasal surgery:",
"     </i>",
"     Toxic shock syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Tendon repair:",
"     </i>",
"     Fibrosis, fixation of tendon prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Tympanoplasty:",
"     </i>",
"     Failure of absorption, hearing loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gelfilm&reg;: There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gelfoam&reg;: Hypersensitivity to porcine collagen; intravascular placement (embolus risk); closure of skin incisions (interferes with healing)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F175498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Do not use in the presence of infection; if signs or symptoms of infection or abscess develop in an area where placed, reoperation may be necessary to remove material and allow drainage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Postpartum bleeding/menorrhagia: Do not use to control postpartum bleeding or menorrhagia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombin: Safety of gelatin products with thrombin has not been evaluated; consult thrombin product labeling for detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Products are not a substitute for surgical technique or conventional hemostasis procedures and should not be used for primary treatment of coagulation disorders. Use minimum amount necessary; remove once hemostasis is attained whenever possible following laminectomy procedures and from foramina in bone. Do not overpack cavities; Gelfoam&reg; expands by absorbing fluid and may interfere with normal function of neighboring structures. It is not recommended to saturate product with an antibiotic solution or dust with antibiotic powder. Do not use in conjunction with methylmethacrylate adhesives.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sterilization: Products cannot be resterilized; unused, opened products should be discarded.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F175502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13862754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered topically, gelatin is completely absorbed; however, the amount of gelatin available systemically following topical application is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Misc",
"     </b>",
"     (Gelfoam Sponge External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12-7 mm (12): $123.77",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13909138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arrests bleeding by forming artificial clot and producing mechanical matrix which facilitates clotting",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8947 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18499=[""].join("\n");
var outline_f18_4_18499=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175512\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175519\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175513\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175515\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175514\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175507\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175495\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13909140\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175508\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175517\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175510\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175498\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299392\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175502\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13862754\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323167\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13909138\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8947\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8947|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_4_18500="Pilar cyst 4";
var content_f18_4_18500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pilar cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18500=[""].join("\n");
var outline_f18_4_18500=null;
var title_f18_4_18501="Eval Rx malignancy ascites";
var content_f18_4_18501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Evaluation and treatment of malignancy-related ascites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 789px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAAG: serum-ascites albumin gradient.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18501=[""].join("\n");
var outline_f18_4_18501=null;
var title_f18_4_18502="Infections due to non-O1/O139 Vibrio cholerae";
var content_f18_4_18502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infections due to non-O1/O139 Vibrio cholerae",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18502/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18502/contributors\">",
"     J Glenn Morris, Jr, MD, MPH&amp;TM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18502/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18502/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18502/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18502/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/4/18502/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3117614\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibrio cholerae is a highly diverse species, with a worldwide distribution in estuarine environments. Only a small subset of V. cholerae strains carry the requisite genes to cause the disease cholera. In an effort to identify cholera-causing strains, investigators studying the \"cholera bacillus\" (V. cholerae) in the early 1990s divided strains into two groups: those that agglutinated with serum from cholera patients (designated as being in O group 1, or V. cholerae O1), and those that did not [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/1\">",
"     1",
"    </a>",
"    ]. This latter strain group (most of which consisted of environmental isolates) has been designated, variously, as \"non-cholera Vibrios&rdquo;, &ldquo;non-agglutinating V. cholerae&rdquo; (also referred to as &ldquo;NAGs&rdquo;), or &ldquo;non-O1 V. cholerae&rdquo;.",
"   </p>",
"   <p>",
"    Subsequent serologic studies have resulted in the identification of over 200 different O groups within the species V. cholerae. While it is now recognized that serotype does not correlate directly with the ability to cause the disease cholera, use of these serologic designations continues to be useful with almost all cholera-causing strains falling into O group 1 or the recently recognized O group 139 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/2\">",
"     2",
"    </a>",
"    ]. However, cholera toxin-producing strains of V. cholerae in other serogroups have also been implicated as the cause of outbreaks of cholera-like illness (O141 and O75 in the United States; O37, O10, O12, O6, and O14 strains from other parts of the world) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In phylogenetic studies, all cholera-associated strains tend to cluster closely together, consistent with the concept that there is an &ldquo;epidemic genotype&rdquo; that includes multiple genes necessary for epidemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, strains outside of these serogroups (commonly referred to as",
"    <span class=\"nowrap\">",
"     &ldquo;non-O1/non-O139",
"    </span>",
"    V. cholerae&rdquo;) are non-pathogenic or asymptomatic colonizers in humans, or cause mild, sporadic illness (such a gastroenteritis, mild wound or ear infections) in otherwise health hosts. However, in persons who are immunocompromised or who have underlying liver disease,",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae strains are capable of causing severe wound infections or sepsis, with high associated mortality",
"    <span class=\"nowrap\">",
"     rates.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-O1/non-O139",
"    V. cholerae strains tend to be highly diverse genetically, and there is not a single route by which they cause human disease. Occurrence of illness is dependent on the particular combination of possible virulence genes carried by the infecting strain, combined with the health status of the host. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae strains carry the genes for and produce cholera toxin (CT), the toxin responsible for the dehydrating diarrhea characteristically seen in epidemic cholera [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. These strains have been associated with gastroenteritis (which, at times, may be severe) but do not appear capable of causing epidemic cholera. In phylogenetic studies, they do not cluster with V. cholerae strains responsible for epidemic disease, suggesting that they lack one or more",
"    <span class=\"nowrap\">",
"     genes/gene",
"    </span>",
"    complexes necessary for production of &ldquo;typical&rdquo; cholera.",
"   </p>",
"   <p>",
"    Another group of",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae strains produce a heat-stable enterotoxin (designated NAG-ST), which closely resembles the heat-stable enterotoxin of enterotoxigenic E. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/11\">",
"     11",
"    </a>",
"    ]. These strains, designated \"enterotoxigenic V. cholerae,\" can cause diarrheal disease in humans, based on observations from volunteer studies as well as epidemiologic studies of outbreaks and sporadic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic studies have identified a type III secretion system in some strains, which may also contribute to virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/15\">",
"     15",
"    </a>",
"    ]. The type III secretion system has been associated with pathogenicity in other diarrheal pathogens (eg, Shigella spp, Salmonella spp, enteropathogenic Escherichia coli, and other Vibrio species) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of other virulence factors in causing disease is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Various extracellular products (eg, cytolysins, hemolysins, a putative exotoxin, and two different RTX toxins) have been identified, but their role in pathogenesis remains to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/15,21-23\">",
"     15,21-23",
"    </a>",
"    ]. In human studies, three",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae strains have been fed to volunteers [23]. One strain, which produced NAG-ST, caused illness; the other two strains did not, although they did colonize the volunteers, consistent with the idea that many isolations of",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae from stool represent identification of non-pathogenic, colonizing strains that may have been acquired incidentally from the environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Septicemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae strains isolated from the blood are heavily encapsulated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/24\">",
"     24",
"    </a>",
"    ], suggesting that the degree of capsule expression is a key element in determining whether sepsis will occur. This polysaccharide capsule provides protection against serum bactericidal activity and phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/25\">",
"     25",
"    </a>",
"    ]. Multiple capsular types have been identified, although data are insufficient to link these polysaccharides with virulence. The association of virulence with encapsulation is similar to that reported for V. vulnificus, with encapsulated",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae capable of producing a V. vulnificus-like clinical syndrome in immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. cholerae are ubiquitous in the marine environment. While generally found in estuarine areas, V. cholerae can grow in fresh water and have been isolated from fresh-water lakes. Vibrios have also been isolated from freshwater insect egg masses (including non-biting midges) as well as from a variety of birds, wild animals, and domestic animals (dogs, cows, goats, chickens, ducks, seagulls, horse, lambs, and bison) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. cholerae are sensitive to temperature. In temperate climates when water temperatures exceed 20&ordm;C (generally in the summer), Vibrios can be isolated easily from water, suspended particulate matter, plankton, algae, sediment, fish, and shellfish. During the winter months,",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae decline markedly in number and are found primarily in sediments. This seasonal variability is reflected in the increase in incidence of",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae and other Vibrio infections seen in temperate areas during summer months.",
"   </p>",
"   <p>",
"    In developed settings, cases of gastroenteritis due to these organisms can almost always be linked to seafood, particularly raw or undercooked shellfish [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/28\">",
"     28",
"    </a>",
"    ]. In developing settings, the pattern is often less clear, due in part to the increased risk of fecal contamination of food and water sources",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cross-contamination of foods by seafood.",
"   </p>",
"   <p>",
"    Wound infections occur in conjunction with environmental exposure to water containing the organism. Septicemia may occur secondary to a wound infection or may occur as a result of ingestion of the organism in shellfish or seafood. Septicemia occurs almost exclusively in persons who have underlying liver disease or are immunosuppressed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Non-O1/non-O139",
"    </span>",
"    V. cholerae have been isolated from 2 to 3 percent of patients with diarrheal illness in tropical areas (including travelers); isolation rates are higher in coastal areas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/27,32,33\">",
"     27,32,33",
"    </a>",
"    ]. In 2008, the CDC Cholera and Other Vibrio Illness Surveillance System reported isolation of",
"    <span class=\"nowrap\">",
"     non-O1/non-O139,",
"    </span>",
"    non-toxigenic V. cholerae from 50 patients in the United States; 56 percent of isolates were from stool, 20 percent from blood, 10 percent from wounds, and the remainder from other sources. Forty percent of these patients were hospitalized, and 4 percent died [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with gastroenteritis due to",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae may have diarrhea, abdominal pain, fever, nausea and vomiting. In one study of 14 US sporadic cases reported to the CDC, all patients had diarrhea (25 percent had bloody diarrhea), 71 percent had fever and 21 percent reported nausea and vomiting; the median duration of illness was 6.4 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/35\">",
"     35",
"    </a>",
"    ]. However, this probably represents the more severe end of the spectrum of illness: cases identified through outbreak investigations have been associated with less severe disease, with an incubation period of 12 to 24 hours and median duration of illness ranging from 12 to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Non-O1/non-O139",
"    </span>",
"    V. cholerae have been isolated from wounds exposed to seawater. Less commonly, they have been implicated as a cause of otitis and pneumonia following near-drowning episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/30,36\">",
"     30,36",
"    </a>",
"    ]. While infection can occur in normal hosts, sepsis and other complications occur almost exclusively among persons who are immunocompromised or have chronic underlying illnesses.",
"   </p>",
"   <p>",
"    Mortality rates for sepsis may range up to 40 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18502/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Patients with sepsis often require prolonged hospitalization in intensive care units, with long-term complications resulting from multiorgan system failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibrio cholerae grow on standard media used for wound and blood cultures. As is true for V. cholerae strains associated with cholera, isolation of the microorganism from stool generally requires a selective media to suppress growth of other organisms, such as thiosulfate, citrate, bile salts, and sucrose (TCBS), on which V. cholerae appears as a typical yellow colony. The laboratory should be alerted regarding cases of diarrhea in which illness due to V. cholerae is suspected so that the appropriate media can be used. Species identification is based on standard biochemical tests.",
"   </p>",
"   <p>",
"    All V. cholerae isolated require further characterization to determine (a) if they carry the gene for cholera toxin; and (b) if they are in serogroups O1 or O139; such testing can generally be done in state health department laboratories (or at the CDC). Strains that carry the gene for cholera toxin, but are not in O groups 1 or 139, will require further",
"    <span class=\"nowrap\">",
"     genetic/serologic",
"    </span>",
"    assessment to see if they might represent a cholera strain outside of the &ldquo;standard&rdquo; cholera serotypes.",
"   </p>",
"   <p>",
"    In general, V. cholerae isolated from a patient in the US (or other developed nation) who lacks a history of travel to a cholera endemic area will almost certainly represent a",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    strain of environmental origin. While these strains can cause serious disease in susceptible hosts, they do not represent the public health threat posed by toxigenic",
"    <span class=\"nowrap\">",
"     O1/O139",
"    </span>",
"    V. cholerae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume repletion is the most important element of therapy in patients with",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae gastroenteritis. In most cases, diarrhea is mild and self-limited. Antimicrobial therapy is reasonable in more severe cases, since among patients with cholera, antibiotic therapy is known to decrease the duration of diarrhea and the excretion of infectious organisms.",
"   </p>",
"   <p>",
"    There are no controlled trials of therapy for gastroenteritis due to",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae strains. Based on clinical trials in cholera and in vitro susceptibility data,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is a reasonable antibiotic choice; alternatives include fluoroquinolones and macrolides. The duration of therapy depends on the antibiotic chosen, as outlined separately for cholera (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wound infections require debridement and antimicrobial therapy. Mild wound infections in patients who do not have significant underlying diseases generally respond well to local wound care and oral antibiotics (such as a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or a fluoroquinolone). Duration of therapy is dictated by clinical response; most patients respond to 5 to 7 days of antibiotics.",
"   </p>",
"   <p>",
"    Patients with septicemia or wound infections in the setting of risk factors for septicemia require aggressive antimicrobial therapy, frequently in an ICU setting. In the absence of data on antimicrobial therapy in sepsis due to",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae, it would appear reasonable to follow the approach to choice of antibiotic therapy used for V. vulnificus, which causes a similar sepsis syndrome in immunocompromised patients. This includes combination therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily), plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (2 g intravenously every eight hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g intravenously daily). Depending on clinical response and the degree of the patient&rsquo;s immunosuppression, one to two weeks (or more) of antimicrobial therapy may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link&amp;anchor=H12#H12\">",
"     \"Vibrio vulnificus infections\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of infection from",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae (as well as other Vibrio species) can be reduced by avoiding the consumption of raw or undercooked shellfish, particularly during warm summer months. This is particularly important for individuals who are immunosuppressed or have serious underlying liver disease. Such individuals should also avoid exposure of wounds to estuarine waters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565955598\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vibrio cholerae is a highly diverse species, of which only a small subset of strains (generally those that produce cholera toxin and are in serogroups O1 and O139) cause the disease cholera. Other V. cholerae (loosely grouped as",
"      <span class=\"nowrap\">",
"       &ldquo;non-O1/non-O139",
"      </span>",
"      V. cholerae&rdquo;) tend to be acquired from environmental sources, and are either non-pathogenic or cause mild illness in humans. However, strains can cause severe and potentially fatal infections in immunocompromised patients or patients with underlying liver disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Non-O1/non-O139",
"      </span>",
"      V. cholerae have been associated with gastroenteritis, wound infections and septicemia. Gastroenteritis is frequently linked to seafood ingestion, particularly raw or undercooked shellfish; it may also occur as a result of fecal contamination of food and water sources. Wound infections occur in conjunction with environmental exposure to water containing the organism. Septicemia occurs almost exclusively in persons who have underlying liver disease or are immunosuppressed, resulting from consumption of the microorganism in seafood or as a complication of a wound infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As is true for all V. cholerae,",
"      <span class=\"nowrap\">",
"       non-O1/non-O139",
"      </span>",
"      strains grow on standard media used for wound and blood cultures. Isolation from stool generally requires a selective media such as TCBS. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For mild diarrhea in otherwise healthy persons, symptomatic treatment, including oral or intravenous rehydration, as necessary, may be sufficient. In more severe cases of diarrhea, antibiotics may reduce the duration of illness; we suggest therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of wound infections requires debridement and antimicrobial therapy. We suggest a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      or fluoroquinolone for treatment of mild wound infections in patients who do not have risk factors for serious infection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of septicemia or wound infections in the setting of risk factors for septicemia (patients who are immunocompromised or with underlying liver disease) requires aggressive antimicrobial therapy; intensive care management may also be needed. We suggest antimicrobial treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      plus a third-generation cephalosporin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/1\">",
"      Gardner AD, Venkatraman KV. The Antigens of the Cholera Group of Vibrios. J Hyg (Lond) 1935; 35:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/2\">",
"      Nair GB, Ramamurthy T, Bhattacharya SK, et al. Spread of Vibrio cholerae O139 Bengal in India. J Infect Dis 1994; 169:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/3\">",
"      Li M, Shimada T, Morris JG Jr, et al. Evidence for the emergence of non-O1 and non-O139 Vibrio cholerae strains with pathogenic potential by exchange of O-antigen biosynthesis regions. Infect Immun 2002; 70:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/4\">",
"      Dalsgaard A, Serichantalergs O, Forslund A, et al. Clinical and environmental isolates of Vibrio cholerae serogroup O141 carry the CTX phage and the genes encoding the toxin-coregulated pili. J Clin Microbiol 2001; 39:4086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/5\">",
"      Tobin-D'Angelo M, Smith AR, Bulens SN, et al. Severe diarrhea caused by cholera toxin-producing vibrio cholerae serogroup O75 infections acquired in the southeastern United States. Clin Infect Dis 2008; 47:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/6\">",
"      Aydanian A, Tang L, Morris JG, et al. Genetic diversity of O-antigen biosynthesis regions in Vibrio cholerae. Appl Environ Microbiol 2011; 77:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/7\">",
"      Rahman MH, Biswas K, Hossain MA, et al. Distribution of genes for virulence and ecological fitness among diverse Vibrio cholerae population in a cholera endemic area: tracking the evolution of pathogenic strains. DNA Cell Biol 2008; 27:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/8\">",
"      Faruque SM, Chowdhury N, Kamruzzaman M, et al. Genetic diversity and virulence potential of environmental Vibrio cholerae population in a cholera-endemic area. Proc Natl Acad Sci U S A 2004; 101:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/9\">",
"      Bi K, Miyoshi SI, Tomochika KI, Shinoda S. Detection of virulence associated genes in clinical strains of vibrio mimicus. Microbiol Immunol 2001; 45:613.",
"     </a>",
"    </li>",
"    <li>",
"     Spira WM, Daniel RR, Ahmed QS, et al. Clinical features and pathogenicity of O group 1 non-agglutinating Vibrio cholerae and other vibrios isolated from cases of diarrhea in Dacca, Bangladesh. In: Symposium on Cholera: Karatsu 1978: Proceedings of the 14th Joint Conference U.S.-Japan Cooperative Medical Science Program Cholera Panel, Takeya J, Zinnaka Y (Eds), Ohta-ku, Tokyo 1978. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/11\">",
"      Arita M, Takeda T, Honda T, Miwatani T. Purification and characterization of Vibrio cholerae non-O1 heat-stable enterotoxin. Infect Immun 1986; 52:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/12\">",
"      Morris JG Jr, Takeda T, Tall BD, et al. Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J Clin Invest 1990; 85:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/13\">",
"      Bagchi K, Echeverria P, Arthur JD, et al. Epidemic of diarrhea caused by Vibrio cholerae non-O1 that produced heat-stable toxin among Khmers in a camp in Thailand. J Clin Microbiol 1993; 31:1315.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson, JA, Salles, CA, Morris, JG Jr. Correlation of heat-stable enterotoxin and capsule type of non-O1 Vibrio cholerae. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, 11-14 October, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/15\">",
"      Chen Y, Johnson JA, Pusch GD, et al. The genome of non-O1 Vibrio cholerae NRT36S demonstrates the presence of pathogenic mechanisms that are distinct from those of O1 Vibrio cholerae. Infect Immun 2007; 75:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/16\">",
"      Makino K, Oshima K, Kurokawa K, et al. Genome sequence of Vibrio parahaemolyticus: a pathogenic mechanism distinct from that of V cholerae. Lancet 2003; 361:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/17\">",
"      Park KS, Ono T, Rokuda M, et al. Functional characterization of two type III secretion systems of Vibrio parahaemolyticus. Infect Immun 2004; 72:6659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/18\">",
"      Okada N, Iida T, Park KS, et al. Identification and characterization of a novel type III secretion system in trh-positive Vibrio parahaemolyticus strain TH3996 reveal genetic lineage and diversity of pathogenic machinery beyond the species level. Infect Immun 2009; 77:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/19\">",
"      Chatterjee S, Ghosh K, Raychoudhuri A, et al. Incidence, virulence factors, and clonality among clinical strains of non-O1, non-O139 Vibrio cholerae isolates from hospitalized diarrheal patients in Kolkata, India. J Clin Microbiol 2009; 47:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/20\">",
"      Bag PK, Bhowmik P, Hajra TK, et al. Putative virulence traits and pathogenicity of Vibrio cholerae Non-O1, Non-O139 isolates from surface waters in Kolkata, India. Appl Environ Microbiol 2008; 74:5635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/21\">",
"      Miyoshi S, Sasahara K, Akamatsu S, et al. Purification and characterization of a hemolysin produced by Vibrio mimicus. Infect Immun 1997; 65:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/22\">",
"      Nishibuchi M, Janda JM, Ezaki T. The thermostable direct hemolysin gene (tdh) of Vibrio hollisae is dissimilar in prevalence to and phylogenetically distant from the tdh genes of other vibrios: implications in the horizontal transfer of the tdh gene. Microbiol Immunol 1996; 40:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/23\">",
"      Miyake M, Honda T, Miwatani T. Purification and characterization of Vibrio metschnikovii cytolysin. Infect Immun 1988; 56:954.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson, JA, Joseph, A, Panigrahi, P, Morris, JG Jr. Frequency of encapsulated versus unencapsulated strains of non-O1 Vibrio cholerae isolated from patients with septicemia or diarrhea, or from environmental strains. American Society for Microbiology Annual Meeting, New Orleans, Louisiana, May 26-30, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/25\">",
"      Johnson JA, Panigrahi P, Morris JG Jr. Non-O1 Vibrio cholerae NRT36S produces a polysaccharide capsule that determines colony morphology, serum resistance, and virulence in mice. Infect Immun 1992; 60:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/26\">",
"      Halpern M, Broza YB, Mittler S, et al. Chironomid egg masses as a natural reservoir of Vibrio cholerae non-O1 and non-O139 in freshwater habitats. Microb Ecol 2004; 47:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/27\">",
"      Morris JG Jr. Non-O group 1 Vibrio cholerae: a look at the epidemiology of an occasional pathogen. Epidemiol Rev 1990; 12:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/28\">",
"      Hlady WG, Klontz KC. The epidemiology of Vibrio infections in Florida, 1981-1993. J Infect Dis 1996; 173:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/29\">",
"      Morris JG Jr, Black RE. Cholera and other vibrioses in the United States. N Engl J Med 1985; 312:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/30\">",
"      Safrin S, Morris JG Jr, Adams M, et al. Non-O:1 Vibrio cholerae bacteremia: case report and review. Rev Infect Dis 1988; 10:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/31\">",
"      Ko WC, Chuang YC, Huang GC, Hsu SY. Infections due to non-O1 Vibrio cholerae in southern Taiwan: predominance in cirrhotic patients. Clin Infect Dis 1998; 27:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/32\">",
"      Finch MJ, Valdespino JL, Wells JG, et al. Non-01 Vibrio cholerae infections in Cancun, Mexico. Am J Trop Med Hyg 1987; 36:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/33\">",
"      Varela G, Olarte J, Perez-Miravete A, Filloy L. Failure to find cholera and noncholera vibrios in diarrheal disease in Mexico City, 1966-67. Am J Trop Med Hyg 1971; 20:925.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/nationalsurveillance/cholera_vibrio_surveillance.html (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/35\">",
"      Morris JG Jr, Wilson R, Davis BR, et al. Non-O group 1 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann Intern Med 1981; 94:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18502/abstract/36\">",
"      Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis 2008; 46:970.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3145 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-0C50FA751B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18502=[""].join("\n");
var outline_f18_4_18502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H565955598\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3117614\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Septicemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565955598\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=related_link\">",
"      Vibrio vulnificus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_4_18503="ECG pace mapping RVOT tachycardia";
var content_f18_4_18503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) during electrophysiologic study showing pace mapping of an idiopathic RVOT tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: 12 lead ECG of spontaneous ventricular tachycardia (VT) in a patient with a structurally normal heart. The VT has a left bundle branch block (LBBB) and an inferior axis morphology, suggesting that the origin is in the right ventricular outflow tract (RVOT). Right panel: A mapping catheter has been positioned in the RVOT and pacing is performed from its tip during sinus rhythm. The \"pace map\" closely approximates the QRS morphology of the spontaneous VT in all 12 leads, suggesting that the mapping catheter is at or near the VT focus.",
"    <div class=\"footnotes\">",
"     S: pacing stimulus artifact.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18503=[""].join("\n");
var outline_f18_4_18503=null;
var title_f18_4_18504="Use of digoxin in heart failure due to systolic dysfunction";
var content_f18_4_18504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of digoxin in heart failure due to systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18504/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18504/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18504/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18504/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18504/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18504/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/4/18504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digitalis has been used for over 200 years to treat patients with heart failure (HF). Evidence from clinical trials supports the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    (the most widely used formulation of digitalis) in patients with left ventricular systolic dysfunction for the treatment of symptoms of HF, particularly in patients with more advanced symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there is no evidence that digoxin improves survival.",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    on hemodynamics, exercise tolerance, and symptoms in patients with HF and use of digoxin in HF will be reviewed here. The use of digoxin in the management of HF should be considered in the context of comprehensive medical therapy of HF with systolic dysfunction (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digitalis acts by inhibiting the Na-K-ATPase pump in myocardial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/3\">",
"     3",
"    </a>",
"    ]. Increased intracellular sodium promotes sodium-calcium exchange, leading to a rise in the intracellular calcium concentration. This results in improved isolated myocyte contractile performance (increased shortening velocity) and overall left ventricular (LV) systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Digitalis also exerts an antiadrenergic action in patients with HF by inhibiting sympathetic outflow and augmenting parasympathetic tone. These actions may contribute to the clinical utility of digitalis in some patients.",
"   </p>",
"   <p>",
"    Digitalis can also be beneficial in HF patients with rapid atrial fibrillation (AF) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/1\">",
"     1",
"    </a>",
"    ]. Digitalis slows the ventricular rate during AF, due largely to increased parasympathetic tone. Through both rate control and improved contractility, digitalis relieves symptoms of HF when associated with AF and a rapid ventricular rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Short-term hemodynamic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have examined the short-term hemodynamic efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    in patients with systolic HF using invasive monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. These studies showed that the administration of 1 mg of intravenous digoxin resulted in an acute improvement in cardiac output, LV stroke work index, mean pulmonary capillary wedge pressure (PCWP), pulmonary artery diastolic pressure, and right atrial pressure, either at rest or with exercise. There is a variable effect on systemic vascular resistance, which is reduced in severe CHF by digoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/5,8\">",
"     5,8",
"    </a>",
"    ], but is stable or even increased in patients with less hemodynamic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY OF CHRONIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials in patients with heart failure have compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/9-17\">",
"     9-17",
"    </a>",
"    ], vasodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/11,18-20\">",
"     11,18-20",
"    </a>",
"    ], or newer oral inotropic agents (xamoterol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , and ibopamine) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/12,13,21\">",
"     12,13,21",
"    </a>",
"    ]. Collectively, these trials showed that digoxin improved clinical symptoms and quality of life, and lowered treatment failure rates, but did not improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One large trial, for example, compared the effects of the initiation of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/11\">",
"     11",
"    </a>",
"    ]. Both treatment regimens were effective. Compared to placebo, digoxin led to an increase in left ventricular ejection fraction (LVEF) of 4.4 percent, a lesser likelihood of requiring an increase in diuretic dose for fluid control, and fewer hospitalizations for treatment failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Trials of digoxin withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two rigorously designed trials (PROVED and RADIANCE) examined the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    withdrawal in patients with stable HF in patients treated with diuretics and digoxin (PROVED) or diuretics, ACE inhibitors and digoxin (RADIANCE) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. These studies randomly assigned patients to continuation of digoxin therapy versus placebo after an eight-week single-blinded stabilization phase. In both trials, digoxin withdrawal resulted in clinical deterioration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In PROVED, at three months, patients withdrawn from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      showed worsened maximal exercise capacity, increased incidence of treatment failures, lower ejection fractions, increased body weight, and higher heart rate [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/15\">",
"       15",
"      </a>",
"      ]. Deterioration occurred even in patients with mild disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In RADIANCE, worsening of HF symptoms was more likely to occur in the group withdrawn from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      for 12 weeks (27 versus 5 percent in those continuing to take digoxin, relative risk 5.9) (",
"      <a class=\"graphic graphic_figure graphicRef72531 \" href=\"UTD.htm?15/9/15517\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/16\">",
"       16",
"      </a>",
"      ]. A deterioration in quality of life was also observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a follow-up study combining data from both RADIANCE and PROVED, the following features were associated with an increased risk of clinical deterioration after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiothoracic ratio &gt;0.57",
"     </li>",
"     <li>",
"      Absence of ACE inhibitor therapy",
"     </li>",
"     <li>",
"      Lower left ventricular ejection fraction",
"     </li>",
"     <li>",
"      Increased age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     DIG trial and patient survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    on patient survival was definitively addressed in the DIG (Digoxin Investigators' Group) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/17\">",
"     17",
"    </a>",
"    ]. This study evaluated almost 6800 patients with symptomatic CHF, a left ventricular ejection fraction &le;45 percent, and normal sinus rhythm who were randomly assigned to digoxin or placebo. An ancillary study included 988 patients with HF and a left ventricular ejection fraction above 45 percent. Most patients had NYHA class II or III heart failure (84 percent) and ischemic heart disease (70 percent); 94 percent were treated with an ACE inhibitor.",
"   </p>",
"   <p>",
"    After three years, the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in survival between the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      and placebo groups; the overall mortality rate was approximately 11 percent per year (",
"      <a class=\"graphic graphic_figure graphicRef80297 \" href=\"UTD.htm?30/9/30877\">",
"       figure 2",
"      </a>",
"      ). Thus, digoxin is different from some other oral positive inotropic agents that decrease survival in patients with HF. It is also different from agents that improve survival: ACE inhibitors, beta blockers, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"       \"Inotropic agents in heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      therapy had a reduction in mortality from worsening HF that did not reach statistical significance (11.6 versus 13.2 percent for placebo, p = 0.06); this benefit was counterbalanced by a significant increase in non-HF cardiac deaths, which included death from arrhythmia (15 versus 13 percent).",
"     </li>",
"     <li>",
"      Patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      therapy had a significant decrease in hospitalization for cardiovascular causes, primarily due to a decrease in hospitalization for HF (26.8 versus 34.7 percent); the reduction in hospitalization rate was similar in patients with either reduced or preserved ejection fraction. This observation suggests a symptomatic benefit similar to the studies noted above. There was also a significant reduction in the combined end points of death from HF and hospitalization for worsening CHF (",
"      <a class=\"graphic graphic_figure graphicRef58166 \" href=\"UTD.htm?37/61/38877\">",
"       figure 3",
"      </a>",
"      ). The benefit of digoxin on these clinical outcomes was independent of age [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent post hoc analyses from the DIG trial demonstrated that when the patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    were stratified according to the serum digoxin concentration, there was a correlation between the digoxin level and patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], such that death and hospitalizations were reduced in patients with a serum digoxin level between 0.5 and 0.9",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    regardless of the ejection fraction or gender (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Optimal digoxin level'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Effect in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective subgroup assessment from the DIG trial assessed the importance of gender on the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/27\">",
"     27",
"    </a>",
"    ]. Among the 1519 women (22 percent), the administration of digoxin was associated with a significant 4.2 percent absolute increase in total mortality (33.1 versus 28.9 percent in those receiving placebo, adjusted hazard ratio 1.23); there were also increases in the secondary outcomes of death from cardiovascular disease or worsening HF. There was no significant overall mortality increase in men. Women also had a less prominent reduction than men in hospitalization for HF with digoxin (hazard ratio 0.87 versus 0.66 compared to placebo).",
"   </p>",
"   <p>",
"    Women had a small but significantly higher serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration at one month (0.9 versus 0.8",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    but there was no difference at one year (0.6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in both groups). Thus, it could not be determined from this analysis whether the increased risk of digoxin in women was due to increased serum concentrations or an unidentified gender-specific toxicity. However, another retrospective analysis of the DIG trial demonstrated a graded relationship between serum digoxin as a continuous variable and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Optimal digoxin level'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physiologic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other studies have evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    on physiologic variables in HF such as exercise performance and neurohumoral activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Exercise performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;An improvement in exercise performance has been the primary end point in many",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    studies, most of which showed that exercise tolerance and peak VO2 improved with digoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/10,13,15,20,21,29,30\">",
"     10,13,15,20,21,29,30",
"    </a>",
"    ]. However, an improvement in peak VO2 has not been seen in some studies that included patients with mild, NYHA class I disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/14,31\">",
"     14,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Neurohumoral activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure is characterized by activation of neurohumoral systems, resulting in progressive increases in the plasma concentrations of norepinephrine, renin, antidiuretic hormone, atrial natriuretic peptide, and endothelin. The degree of neurohumoral activation generally varies directly with the severity of the CHF and inversely with patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in cardiac output induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    would be expected to reduce neurohumoral activation. In addition, digoxin may directly decrease sympathetic activation, perhaps by normalization of pathologic baroreflex responses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reductions in the plasma norepinephrine concentration have been demonstrated after the administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and with chronic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/18,38,39\">",
"     18,38,39",
"    </a>",
"    ]. In one report, plasma norepinephrine levels decreased (from a mean of 552",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    to 390",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and parasympathetic activity increased in 26 patients receiving oral digoxin for the first time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were noted in the Dutch Ibopamine Multicenter Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/39\">",
"     39",
"    </a>",
"    ]. In this study, 161 patients were randomly assigned to ibopamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , or placebo. Patients randomly assigned to digoxin therapy had a significant reduction in plasma norepinephrine and renin activity after six months compared to an increase with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OPTIMAL DIGOXIN LEVEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    possesses a narrow toxic to therapeutic window. Toxic effects include the induction of arrhythmias, conduction disturbances, and, in severe cases, constitutional symptoms such as nausea, vomiting, and visual disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trials in patients with normal sinus rhythm that demonstrated hemodynamic benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    therapy have had mean serum digoxin concentrations ranging from 0.7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/11\">",
"     11",
"    </a>",
"    ] to 1.75",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/10\">",
"     10",
"    </a>",
"    ]. The doses used to achieve these values ranged from 0.125",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to as high as 0.5 mg per day in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/13\">",
"     13",
"    </a>",
"    ]. The DIG trial, for example, maintained digoxin levels between 0.5 and 1.5",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    in most patients, approximately 70 percent of whom received 0.25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    according to a dosing algorithm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of patients in the PROVED and RADIANCE trials found no relationship between the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration and any clinical end point, including worsening of HF, change in LVEF, or time on a treadmill [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/40\">",
"     40",
"    </a>",
"    ]. On multivariate analysis, patients taking digoxin did significantly better than those withdrawn from the drug, but the serum concentration (&lt;0.9, &gt;0.9 to 1.2, and &gt;1.2",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    did not correlate with outcome.",
"   </p>",
"   <p>",
"    In contrast, a significant correlation between the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration and survival was found in several post hoc analyses from the DIG trial, with many more participants and much longer follow-up than PROVED or RADIANCE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/25,26,28\">",
"     25,26,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first such analysis from the DIG trial was restricted to men with an LVEF &le;45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/25\">",
"     25",
"    </a>",
"    ]. The 3782 subjects were divided into four groups: those receiving placebo, and those with a serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration at one month of 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    0.9 to 1.1",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and &ge;1.2",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    The all-cause mortality at 37 months was significantly",
"    <strong>",
"     lower",
"    </strong>",
"    for those with a serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration of 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    than for the placebo group (29.9 versus 36.2 percent), while mortality was",
"    <strong>",
"     increased",
"    </strong>",
"    for those with a serum digoxin concentration above 1.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef80620 \" href=\"UTD.htm?24/42/25262\">",
"     figure 4",
"    </a>",
"    ). These associations remained significant after multivariable adjustment.",
"   </p>",
"   <p>",
"    There was a similar relationship between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentrations and survival in the 318 women in whom sufficient data were available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      concentrations of 0.5 to 0.9",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      had a nonsignificant trend toward a lower rate of mortality; the failure to show a significant mortality benefit in women may have been related to the relatively small number (318) of eligible patients.",
"     </li>",
"     <li>",
"      At serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      concentrations of 1.2 to 2.0",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      women had a significant 33 percent increase in mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the 2009 focused update of the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    HF guidelines, digitalis can be beneficial in patients with reduced LVEF and current or prior symptoms of heart failure to decrease hospitalization for HF.",
"   </p>",
"   <p>",
"    The 2008 European Society of Cardiology (ESC) heart failure guidelines recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    (in addition to an angiotensin converting enzyme inhibitor) in patients in sinus rhythm with symptomatic HF and an LVEF &le;40 percent to improve ventricular function and patient well-being with reduction in hospitalization for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation and maintenance dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is generally 0.125 to 0.25 mg daily. Loading doses of digoxin (as may be used for rate control in patients with atrial fibrillation) are not indicated in patients with HF.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is NOT indicated for primary stabilization of patients with an acute exacerbation of HF symptoms. Patients with acute decompensated heart failure should receive appropriate treatment and digoxin treatment may be initiated after stabilization (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SAFETY AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is contraindicated in patients with significant sinus or atrioventricular block (unless the block has been addressed with a permanent pacemaker). Digoxin should be used with caution when taken in combination with other drugs that depress sinus or atrioventricular nodal function or affect digoxin levels (eg, beta blockers).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    in patients with heart failure due to systolic dysfunction. These recommendations are in general agreement with the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80859 \" href=\"UTD.htm?41/45/42716\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with left ventricular systolic dysfunction (LVEF &lt;40 percent) who continue to have NYHA functional class II, III and IV symptoms (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 3",
"      </a>",
"      ) despite optimal therapy (eg, ACE inhibitor or ARB, beta blocker, and, if necessary for fluid control, a diuretic) we suggest administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Efficacy of chronic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest maintaining",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      levels between 0.5 and 0.8",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in both men and women (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Higher serum levels should be avoided since they are associated with an increased risk of toxicity, without clear evidence of enhanced efficacy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Optimal digoxin level'",
"      </a>",
"      above.) A discussion of digoxin dosing and monitoring is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment with digoxin: initial dosing, monitoring, and dose modification\", section on 'Monitoring serum digoxin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although we have not altered our use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      in women with HF, the possible increase in risk suggests that a higher threshold may be warranted for instituting digoxin therapy in women. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Effect in women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because evidence demonstrates that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      therapy provides symptom relief but not mortality benefit, we recommend that digoxin should",
"      <strong>",
"       not",
"      </strong>",
"      be used in asymptomatic patients with left ventricular systolic dysfunction and normal sinus rhythm (",
"      <a class=\"graphic graphic_table graphicRef67792 \" href=\"UTD.htm?40/15/41212\">",
"       table 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/2\">",
"       2",
"      </a>",
"      ]&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"       \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because alternative therapies with superior short",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      long-term safety and efficacy profiles are available (eg, ACE inhibitors, intravenous diuretics, and other intravenous inotropes) we suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      should",
"      <strong>",
"       NOT",
"      </strong>",
"      be used as primary therapy for the stabilization of patients with acutely decompensated HF (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of acute decompensated heart failure: General considerations\", section on 'Treatment goals for acute versus chronic HF'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    may be initiated in the early treatment of such patients if it is anticipated to be part of a long-term treatment strategy in those who were already treated with appropriate medical therapy prior to decompensation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      but are not yet treated with conventional first line therapy for HF, including an ACE inhibitor or ARB, and a beta blocker. In such patients, we suggest that digoxin should be continued during initiation of these medications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). After these medications have been initiated, we suggest a trial of digoxin withdrawal if the patient is asymptomatic, in sinus rhythm, and has improved systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18504/abstract/1\">",
"       1",
"      </a>",
"      ]&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Trials of digoxin withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are additional considerations with regard to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    in HF patients who also have atrial fibrillation (AF) requiring rate control.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with chronic HF due to systolic dysfunction and atrial AF requiring rate control, we recommend beta blockers as initial therapy, since they are recommended in such patients for general HF treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, beta blockers may need to be initiated at lower doses with careful titration in patients with severe left ventricular systolic dysfunction. If a second agent is necessary to achieve adequate rate control, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"       \"Atrial fibrillation in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with decompensated HF, the initiation of or increase in the dose of beta blockers is contraindicated. If such a patient also has rapid AF requiring rate control, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/1\">",
"      Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006; 113:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/2\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/3\">",
"      Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/4\">",
"      McMahon WS, Holzgrefe HH, Walker JD, et al. Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure. J Am Coll Cardiol 1996; 28:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/5\">",
"      Gheorghiade M, St Clair J, St Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987; 9:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/6\">",
"      Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989; 13:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/7\">",
"      Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol 1985; 56:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/8\">",
"      Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980; 303:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/9\">",
"      Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med 1982; 306:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/10\">",
"      Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988; 61:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/11\">",
"      Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA 1988; 259:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/12\">",
"      Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group. Lancet 1988; 1:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/13\">",
"      DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/14\">",
"      Fleg JL, Rothfeld B, Gottlieb SH. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial. J Am Coll Cardiol 1991; 17:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/15\">",
"      Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/16\">",
"      Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/17\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/18\">",
"      Alicandri C, Fariello R, Boni E, et al. Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. J Cardiovasc Pharmacol 1987; 9 Suppl 2:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/19\">",
"      Kromer EP, Elsner D, Riegger GA. Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm. J Cardiovasc Pharmacol 1990; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/20\">",
"      Davies RF, Beanlands DS, Nadeau C, et al. Enalapril versus digoxin in patients with congestive heart failure: a multicenter study. Canadian Enalapril Versus Digoxin Study Group. J Am Coll Cardiol 1991; 18:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/21\">",
"      Alicandri C, Fariello R, Boni E, et al. Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. J Cardiovasc Pharmacol 1989; 14 Suppl 8:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/22\">",
"      Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol 1997; 30:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/23\">",
"      Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. Am Heart J 1998; 135:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/24\">",
"      Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001; 38:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/25\">",
"      Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/26\">",
"      Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/27\">",
"      Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/28\">",
"      Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/29\">",
"      Packer M. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol 1988; 12:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/30\">",
"      Sullivan M, Atwood JE, Myers J, et al. Increased exercise capacity after digoxin administration in patients with heart failure. J Am Coll Cardiol 1989; 13:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/31\">",
"      Tanabe Y, Takahashi M, Momotsu T, et al. Effect of digoxin on exercise performance in mildly symptomatic patients with idiopathic dilated cardiomyopathy and sinus rhythm. Jpn Heart J 1994; 35:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/32\">",
"      Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/33\">",
"      Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87:VI5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/34\">",
"      Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/35\">",
"      Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation 1984; 69:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/36\">",
"      Schobel HP, Oren RM, Roach PJ, et al. Contrasting effects of digitalis and dobutamine on baroreflex sympathetic control in normal humans. Circulation 1991; 84:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/37\">",
"      Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989; 80:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/38\">",
"      Krum H, Bigger JT Jr, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995; 25:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/39\">",
"      van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993; 22:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/40\">",
"      Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002; 39:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18504/abstract/41\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3514 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18504=[""].join("\n");
var outline_f18_4_18504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Short-term hemodynamic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY OF CHRONIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Trials of digoxin withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIG trial and patient survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Effect in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physiologic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Exercise performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Neurohumoral activation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OPTIMAL DIGOXIN LEVEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SAFETY AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3514\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3514|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/9/15517\" title=\"figure 1\">",
"      Digoxin in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/9/30877\" title=\"figure 2\">",
"      Digoxin and total mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/61/38877\" title=\"figure 3\">",
"      Digoxin and HF mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/42/25262\" title=\"figure 4\">",
"      Digoxin level and survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3514|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 1\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/45/42716\" title=\"table 2\">",
"      ACC AHA Rx HF other diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 3\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/15/41212\" title=\"table 4\">",
"      ACC AHA Rx asym LV dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=related_link\">",
"      Treatment with digoxin: initial dosing, monitoring, and dose modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_4_18505="JXG multiple scalp";
var content_f18_4_18505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68597%7EDERM%2F81058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68597%7EDERM%2F81058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple yellow-orange papules and plaques on the scalp of a child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Kate P&uuml;ttgen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple scalp lesions in a young child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" style=\"FONT-STYLE: italic\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18505=[""].join("\n");
var outline_f18_4_18505=null;
var title_f18_4_18506="Bone and joint complications in sickle cell disease";
var content_f18_4_18506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bone and joint complications in sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18506/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18506/contributors\">",
"     Mary Nell Suell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18506/contributors\">",
"     Alex George, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18506/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18506/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18506/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18506/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/4/18506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/4/18506/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/4/18506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sickle cell disease (SCD) is characterized by a marked heterogeneity in clinical and hematologic severity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], bone and joint problems are the most common manifestations. Pain, caused by vaso-occlusive crises (VOC), may occur as often as every week or as rarely as once a year. Many patients also suffer from the long-term consequences of VOC in the musculoskeletal system, such as avascular necrosis of the femoral heads or collapsed vertebral bodies, leading to a chronic state of pain in addition to the more acute painful crises.",
"   </p>",
"   <p>",
"    Bone and joint complications in SCD are discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/3\">",
"     3",
"    </a>",
"    ]. Other manifestations of the disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with SCD is discussed separately in an overview topic and in individual topics on the treatment of specific disease manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VASO-OCCLUSIVE CRISES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated painful vaso-occlusive crises (VOCs), also referred to as &ldquo;pain crises&rdquo; or &ldquo;sickle crises&rdquo;, are the hallmark of sickle cell disease (SCD). VOCs can lead to bone infarcts, necrosis, and, over time, degenerative changes in marrow-containing bone. VOCs can occur in early infancy and into adulthood, and are a major cause of hospitalization in SCD. Among patients with SCD in the United States, almost 90 percent of all visits to the emergency department are for painful crises, as are almost 70 percent of all hospitalizations, with an average duration of 8 to 11 days. Similar numbers are found in sickle cell patients in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/4\">",
"     4",
"    </a>",
"    ]. In the National Heart, Lung, and Blood Institute's Cooperative Study of SCD, 3578 patients were followed prospectively. During 18,356 patient-years of observation, 12,290 episodes of pain were observed, with an average rate of 0.8, 1.0, and 0.4 episodes per patient-year in subjects with HbSS disease, sickle cell beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia, and HbSC disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/1\">",
"     1",
"    </a>",
"    ]. However, even within the same genotype, marked variation occurred with regard to frequency and severity of VOC. As an example, almost 40 percent of all patients had no episode of pain during the observation period, whereas 5 percent of the patients accounted for one-third of all episodes. However, concomitant alpha thalassemia trait and higher hemoglobin S levels appear to be associated with more frequent pain crises [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of sickle cell disease hinges on the relative insolubility of sickle hemoglobin and its tendency to polymerize into long triple-helical chains when deoxygenated. The primary determinants of sickle hemoglobin polymerization are the relative concentration of hemoglobin S in the erythrocyte, and the extent of hemoglobin deoxygenation. A vascular environment in which blood flow is slow and hemoglobin undergoes progressive deoxygenation is therefore primed for the precipitation and polymerization of sickle hemoglobin. Hemoglobin polymerization subsequently drives several changes in the erythrocyte, including mechanical disruption of cell integrity, ion fluxes across the cell membrane that result in cell dehydration, and alterations in the composition of the cell membrane. The net result of all these perturbations is increased fragility of the erythrocyte, manifested as chronic hemolytic anemia, and decreased deformability and increased \"stickiness\" of the erythrocyte that result in aberrant adhesion to other blood cells and the vascular endothelium, causing vaso-occlusion. Chronic hemolysis and episodic vaso-occlusion induce numerous systemic, pathologic processes, including ischemia-reperfusion injury, inflammatory responses, activation of the coagulation system, nitric oxide depletion, and endothelial dysfunction, that cumulatively result in the myriad clinical manifestations of sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/6\">",
"     6",
"    </a>",
"    ]. More extensive discussions of the pathophysiology of VOC are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=see_link\">",
"     \"Vasoocclusion in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of sickle cell-associated musculoskeletal pain is a subject of much study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. Vaso-occlusion can occur in a wide range of vascular beds, but the most common sites of clinically apparent stasis are the bone marrow, periosteum, and deep muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/13\">",
"     13",
"    </a>",
"    ]. The slow progression of erythrocytes through marrow sinusoids and capillary beds, and the relatively hypoxic tissue environment together increase the extent of hemoglobin deoxygenation and the likelihood of red cell sickling. Complex interactions between sickled RBCs, activated WBCs, platelets, and endothelial cells, and circulating plasma proteins then lead to multicellular aggregates that eventually cause clinically significant occlusion of tissue vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/14\">",
"     14",
"    </a>",
"    ]. The inflammatory response to ischemia and infarction leads to pain in the surrounding tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/15\">",
"     15",
"    </a>",
"    ]. Activated monocytes probably play an important role in enhancing vaso-occlusion through the production of inflammatory cytokines and the recruitment of other white blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/16\">",
"     16",
"    </a>",
"    ]. Inflammatory mediators, such as interleukin (IL)-6, IL&ndash;8, and tumor necrosis factor, are not consistently elevated during VOC, whereas plasma endothelin-1 and prostaglandin E2 tend to be higher during crises [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/17\">",
"     17",
"    </a>",
"    ]. Substance P, a mediator of neurogenic inflammation and pain, also is increased during VOC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/7\">",
"     7",
"    </a>",
"    ]. Heme, liberated during vaso-occlusive events from damaged red cells, is itself a potent inducer of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/18\">",
"     18",
"    </a>",
"    ], and free hemoglobin may accentuate vascular constriction by depleting available nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/10,19,20\">",
"     10,19,20",
"    </a>",
"    ]. Arginase released from lysed erythrocytes also contributes to impaired nitric oxide signaling by depleting available arginine, a substrate for endothelial nitric oxide synthase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain in the ribs and sternum can lead to splinting and hypoventilation, which, in combination with fat emboli, increases the risk for developing acute chest syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/22\">",
"     22",
"    </a>",
"    ]. Repeated VOC in vertebral bodies may lead to a collapse of the bony structure, leading to chronic pain, which sometimes can be managed only by the use of a brace [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Acute chest syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A further unexplored area is perception and interpretation of pain by the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of a vaso-occlusive crisis (VOC) in a bony structure is dominated by an acute onset of deep-seated pain, often described by the patient as \"typical sickle cell pain.\" Mild erythema and warmth, as well as local tenderness on palpation, are usually present, and many patients have a low-grade fever. Pain can vary from mild (ie, barely interfering with normal activities) to excruciating (ie, \"worse than breaking a leg\"). Of note, other than the localized erythema and warmth described above, there are no specific findings on clinical exam or laboratory evaluation that correlate with the diagnosis of a VOC. As such, the gold standard for both diagnosis and management of a pain crisis is the patient's self-report of the location and severity of pain.",
"   </p>",
"   <p>",
"    Differentiation between VOC and osteomyelitis can be difficult. However, VOC is much more common than osteomyelitis, usually responds within a few days to aggressive pain management, and typically presents in an otherwise well individual with little or no fever. Patients with fever of 101.5&ordm;F (38.5&ordm;C) or higher should have blood cultures and a complete blood count obtained to evaluate for the possibility of infection. In one case-control study of patients with SCD that compared patients who had osteomyelitis with patients who had uncomplicated pain crises, the major differentiating factors between VOC and osteomyelitis were the preceding duration of fever (zero versus one days) and pain (two versus five days), swelling of the affected limb (absent versus present), and localized pain (&gt;1 painful site versus a single localized site) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Osteomyelitis and septic arthritis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39961?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of fever in sickle cell disease\", section on 'Acute management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Musculoskeletal VOC typically occur in the long bones. As an example in a study of 192 children with SCD, bony infarctions occurred most commonly in the humerus (38 percent), tibia (23 percent), and femur (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/26\">",
"     26",
"    </a>",
"    ]. Although the long bones are affected most commonly, children and adults can present with VOC of virtually any bony structure containing red (erythropoietic) marrow, including ribs, sternum, vertebral bodies, and skull (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74577 graphicRef51573 \" href=\"UTD.htm?10/49/11032\">",
"     image 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic findings are not specific for VOC. In patients with VOC, plain radiographs initially do not show abnormalities, but the necrosis and remodeling of bone results in increased radiographic density within one or two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/28\">",
"     28",
"    </a>",
"    ]. Vertebral bodies typically show a biconcave deformity, caused by marrow necrosis and subsequent collapse, and can result in severe chronic back pain (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68218 \" href=\"UTD.htm?12/51/13104\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a typical VOC, bone scans with Technetium-99m methylene diphosphonate show increased uptake, whereas a bone marrow scan with Technetium sulfur colloid often shows decreased or absent uptake in the area of the VOC [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In a study of 14 subjects with 28 painful episodes, magnetic resonance imaging (MRI) showed increased signals on intermediate and T2-weighted images in 36 percent of painful episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/32\">",
"     32",
"    </a>",
"    ]. However, neither finding is specific for VOC and may be similar in a case of osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107811541\">",
"    <span class=\"h3\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of vaso-occlusive crises consists of hydration (100 to 150 percent of normal daily fluid needs, given by mouth or intravenously), warm packs to the affected area(s), and a combination of analgesic and anti-inflammatory medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the management of sickle cell disease\", section on 'Pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prompt intervention is essential and may prevent many visits to the emergency department and subsequent hospitalizations. All patients with SCD should be educated to start treatment of VOC at home with heating pads, oral fluids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , as well as a mild opiate (eg, acetaminophen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. If appropriate home management fails to relieve the pain adequately, patients need to be assessed for the need for intravenous opiates in conjunction with the above mentioned interventions.",
"   </p>",
"   <p>",
"    It is essential that patients with sickle cell-related pain are triaged rapidly and given appropriate doses and frequency of analgesic medications. Patients and their parents often know which analgesic drug at what dose will provide the best relief, and medical personnel should take such knowledge into account [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Many SCD centers have established dedicated staff and space to function as a day hospital, allowing immediate treatment of pain crises by knowledgeable staff, decreasing the lag time typically encountered in crowded emergency departments, and minimizing the need for hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/4,36\">",
"     4,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain medication should never be withheld from children and adolescents with SCD for fear of rewarding drug-seeking behavior or testing the validity of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/37\">",
"     37",
"    </a>",
"    ]. This principle also applies to the majority of adults with SCD. For adults with known concerns regarding drug-seeking behavior, a detailed care plan can be helpful in setting patient and caregiver expectations.",
"   </p>",
"   <p>",
"    Severe pain is managed best with frequent boluses or a continuous infusion of an opioid, along with appropriate monitoring of oxygenation and cardiopulmonary status. A prospective trial of patient-controlled analgesia (PCA) compared with continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    infusion revealed that the PCA group had a lower cumulative use of opioid analgesics, fewer adverse effects of opioid therapy, and shorter (albeit nonsignificant) hospital stays [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/38\">",
"     38",
"    </a>",
"    ], indicating that PCA is in general a viable and effective strategy for SCD pain management. Incentive spirometry (or blowing bubbles for young children) should be encouraged, and ambulation should be maintained as much as possible to prevent hypoventilation, atelectasis, and subsequent acute chest syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/39\">",
"     39",
"    </a>",
"    ]. Stool softeners or a laxative are recommended for all patients receiving opioids on a regular schedule.",
"   </p>",
"   <p>",
"    Reviews of hospitalization rates among pediatric SCD patients revealed a high re-admission rate within 30 days, especially for patients admitted for pain management, and revealed that outpatient follow-up was associated with significant lowering of this re-admission rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. These findings highlight the importance of good pain control prior to discharge, a detailed home pain management plan, and appropriate outpatient follow-up for patients admitted for sickle cell pain crises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SCD or sickle-beta thalassemia (ie, HbS-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia) and repeated episodes of VOC should be considered for therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (HU), which can decrease the frequency of painful episodes in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications, dosing, efficacy, and toxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    in SCD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6833306\">",
"    <span class=\"h3\">",
"     Other approaches",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A promising approach to the therapy of VOC is the development of agents that target the underlying pathophysiology of vaso-occlusion. Among these agents are amphipathic polymers that appear to nonspecifically reduce blood viscosity and RBC adhesion to the vascular wall [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/44\">",
"       44",
"      </a>",
"      ], and P-selectin antagonists that specifically target receptor-mediated interactions between blood cells and the vascular endothelium [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Pre-clinical and clinical trials are underway to determine if these agents will be beneficial in the prophylaxis and treatment of acute VOC.",
"     </li>",
"     <li>",
"      Oxygen supplementation has no role in the normoxic patient with VOC, and the use of glucocorticoids or transfusion is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. Glucocorticoid use in patients with SCD, in particular, appears to carry a risk of \"rebound\" VOC [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/50,51\">",
"       50,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Current treatment guidelines for SCD generally recommend avoiding RBC transfusion for acute VOC unless there is also symptomatic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/52\">",
"       52",
"      </a>",
"      ]. Chronic transfusion, while empirically shown to be effective in patients with recurrent pain crises [",
"      <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/53\">",
"       53",
"      </a>",
"      ], is resource-intensive and carries the risks of alloimmunization, iatrogenic iron overload, and infection, and is generally not used unless the patient is unable or unwilling to tolerate other therapies, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"       \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DACTYLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dactylitis (hand-foot syndrome) is the occurrence of painful vasoocclusive crises in the small bones of hands and feet that typically occurs in infants with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/54\">",
"     54",
"    </a>",
"    ]. As many as 45 percent of all children with HbSS disease will have been affected by this complication by the time they reach two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/55\">",
"     55",
"    </a>",
"    ]; dactylitis occurs much less commonly in HbSC disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/54\">",
"     54",
"    </a>",
"    ]. In an analysis of adverse outcomes in children, it was found that dactylitis within the first year of life (as well as severe anemia and leukocytosis within the first two years) predicts the possibility of severe disease, defined as disease associated with serious adverse events (eg, death, stroke, frequent pain, or recurrent acute chest syndrome) later in life (",
"    <a class=\"graphic graphic_figure graphicRef59314 \" href=\"UTD.htm?40/51/41790\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/56\">",
"     56",
"    </a>",
"    ]. Dactylitis is rarely seen in children older than four years of age, presumably because, as the child grows older, the red marrow in these small bones is replaced by fat and fibrous tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dactylitis presents with a painful, often symmetrical swelling of hands or feet, often accompanied by mild erythema and low-grade fever. Except for soft tissue swelling, no immediate radiological changes are visible; recurrent episodes will lead to a mottled appearance of the small bones of the hands or feet. The differential diagnosis includes osteomyelitis, which usually affects only a single digit or bone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of hydration, analgesic and anti-inflammatory medication, and hot packs. Recurrent episodes are not uncommon, and in some patients the early introduction of a disease-modifying agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , may be considered. In the BABY HUG trial, in which 167 infants and young children with sickle cell disease were randomized to receive hydroxyurea or placebo, there was a significantly lower rate of dactylitis in the hydroxyurea-treated group, establishing the efficacy of this agent in preventing this early complication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In most cases, the radiological abnormalities disappear over time, although a permanent shortening of the involved digits may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OSTEOMYELITIS AND SEPTIC ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the early decrease in splenic function, bacterial infections of bone and joints are common in children with SCD. Areas of infarcted bone or bone marrow are typical sites for infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Genetic polymorphisms of mannose-binding proteins and HLA class II alleles also might influence the susceptibility to infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although blood cultures during septic events most commonly yield Streptococcus pneumoniae or Haemophilus influenzae, osteomyelitis is usually due to Salmonella or other gram-negative organisms, such as Escherichia coli, in the United States and Europe. Staphylococcus aureus, the most common cause of osteomyelitis in normal hosts, probably accounts for only one-fourth of all cases in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/54,57,58,66-70\">",
"     54,57,58,66-70",
"    </a>",
"    ]. By contrast, in sub-Saharan Africa and the Middle East, S. aureus is the most common pathogen identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link&amp;anchor=H7#H7\">",
"     \"Hematogenous osteomyelitis in adults\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Septic arthritis is less common than osteomyelitis in individuals with SCD. In a prospective study of 14 patients with SCD and septic arthritis, Staphylococcus was found to be the infecting organism in 11 and Salmonella in only two [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/72\">",
"     72",
"    </a>",
"    ]. Other authors did not find any predominating organism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/66\">",
"     66",
"    </a>",
"    ]. In the absence of a positive culture, the possibility of a rheumatic manifestation, especially in female adolescents, should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of osteomyelitis or septic arthritis is often similar to a vaso-occlusive crisis, and the diagnosis is often difficult to make. Infectious episodes are more likely to be associated with a prolonged duration of fever and pain, and swelling and pain that is localized to a single site [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, local warmth, tenderness, swelling are common in both VOC and osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal diagnostic approach in patients with suspected osteomyelitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    septic arthritis remains unclear. Plain films, bone scintigram, and MRI all show positive results in both conditions, and have been used with variable success (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70418 \" href=\"UTD.htm?11/4/11342\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/30,31,74-76\">",
"     30,31,74-76",
"    </a>",
"    ]. Biopsy or aspiration of a suspected locus of infection is considered the gold standard for diagnosis of",
"    <span class=\"nowrap\">",
"     osteomyelitis/septic",
"    </span>",
"    arthritis, but even this procedure may not definitively establish the diagnosis, especially if no infectious agent is found [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/66\">",
"     66",
"    </a>",
"    ]. Both VOC and bony infections will show an infiltrate of neutrophils and macrophages, as well as necrotic tissue. Despite these difficulties, it is important to try to make a diagnosis of osteomyelitis or septic arthritis, especially if the patient is febrile, appears ill, or complains of severe localized pain despite aggressive pain management [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles for treatment of sickle cell-related osteomyelitis and septic arthritis are not different from those in normal hosts, but the choice of antibiotics should take into account the different pathogenic organisms commonly found in this group of patients. Given the risk of acute chest syndrome with the use of general anesthesia, invasive procedures, such as bone biopsy or debridement, should be performed with caution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of the management of sickle cell disease\", section on 'Specific infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OSTEONECROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis of the femoral or humeral head (also called avascular necrosis [AVN]), is a well-described complication of SCD. Of 2590 patients enrolled in the Cooperative Study of SCD and followed for an average of 5.6 years, 10 percent had AVN at entry [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/78\">",
"     78",
"    </a>",
"    ]. Patients with HbSS and concomitant alpha thalassemia were at highest risk (4.5 cases per 100 patient-years, compared with 2.4 in patients with HbSS without concomitant alpha thalassemia and 1.9 cases per 100 patient-years in HbSC disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/78\">",
"     78",
"    </a>",
"    ]. High levels of HbF appear to be somewhat protective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Osteonecrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22080169\">",
"    <span class=\"h2\">",
"     Humeral head",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study of 2524 patients with SCD entered into a prospective study, 5.6 percent had radiographic evidence of osteonecrosis in one or both shoulders at study entry [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/81\">",
"     81",
"    </a>",
"    ]. The highest age-adjusted incidence was found in patients with HbSS and concomitant alpha thalassemia as well as in those with HbS-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia (4.8 per 100 patient-years). Of interest, no patient with HbS-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia younger than age 25 had humeral head osteonecrosis on study entry.",
"   </p>",
"   <p>",
"    Osteonecrosis of the humeral head in adults with SCD has a high likelihood of progressing to humeral head collapse. This was shown in a study of 82 adult patients (104 involved shoulder joints) with SCD and symptomatic osteonecrosis of the humeral head [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/82\">",
"     82",
"    </a>",
"    ]. At an average of 20 years of follow-up, collapse had occurred in 89 shoulders (86 percent), with a median interval between the onset of pain and collapse of eight years (range: 6 months to 17 years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22080134\">",
"    <span class=\"h2\">",
"     Femoral head",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107812031\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVN of the femoral head is characterized by hip pain with weight bearing. AVN of the femoral head is found in individuals of all ages with SCD, including children as young as five years. The prevalence of this complication increases with age; in one study, involvement was bilateral in 54 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/78\">",
"     78",
"    </a>",
"    ]. The same study found radiologic evidence of unilateral or bilateral osteonecrosis of the humeral head in 5.6 percent of patients at the time of study entry, but only 21 percent of patients reported pain in one or both hips [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural course of AVN of the hip shows progression from childhood into adult life. In 52 patients (95 affected hips) diagnosed with AVN of the hip in childhood and studied at an average of 19 years after onset of AVN, 80 percent of the affected hips were painful and showed permanent damage (eg, decreased mobility, abnormal gait, and limb-length discrepancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/83\">",
"     83",
"    </a>",
"    ]. The first symptom of pain had been noted at an average age of 12 years (range 7 to 15 years), and 15 of the 95 affected hips required a surgical procedure at an average of 30 years (range 18 to 32 years) post onset of AVN [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/83\">",
"     83",
"    </a>",
"    ]. The success of arthroplasties was very limited, in many cases not allowing for better or prolonged mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were observed in the Cooperative Study of SCD, in which the life expectancy of a hip prosthesis was estimated. The chance of requiring a surgical revision was 8, 20, and 30 percent during the first year, within three years, and within 4.5 years after the procedure, respectively, with a mean interval of 27 months (range: 11 to 53 years) between procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107812038\">",
"    <span class=\"h3\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although AVN is associated with pain, almost half of patients in whom AVN was diagnosed radiologically had no pain at time of diagnosis; 21 percent of these patients who initially had no pain became symptomatic after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/78\">",
"     78",
"    </a>",
"    ]. In a second study of 121 patients with sickle cell disease and asymptomatic osteonecrosis of the femoral head that was contralateral to a hip with symptomatic osteonecrosis, 91 of the 121 hips at risk (75 percent) ultimately developed intractable pain and required surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that radiologic assessment of the contralateral hip should be considered in patients with SCD diagnosed with femoral head AVN. Additionally, given the potential value of early surgical intervention, there may be utility to periodic radiological screening of the hips in patients with high clinical risk for AVN, such as those with frequent VOCs, a high baseline hemoglobin concentration, or concurrent alpha-thalassemia trait. However, no clinically effective schedule for such screening has been established to date. In the absence of data, AP and frog lateral views of the pelvis annually or every other year might be reasonable for a high-risk patient.",
"   </p>",
"   <p>",
"    Staging of hip AVN is largely based on radiologic findings. An initial five-stage system relied on findings on plain-film radiographs with subsequent modifications to incorporate findings on MRI analysis. There are numerous staging systems in existence, but all rely on a combination of plain-film and MRI findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/85\">",
"     85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extent of the femoral head lesion on MRI (&lt;15 percent; 15 to 30 percent; &gt;30 percent)",
"     </li>",
"     <li>",
"      Extent of involvement of the articular surface (&lt;15 percent; 15 to 30 percent; &gt;30 percent)",
"     </li>",
"     <li>",
"      Acetabular changes (mild, moderate, or severe)",
"     </li>",
"     <li>",
"      Extent of femoral head collapse or depression (&lt;15 percent or 2 mm; 15 to 30 percent or 2 to 4 mm; &gt;30 percent or 4 mm)",
"     </li>",
"     <li>",
"      Other radiographic findings (sclerosis; cysts; crescent sign)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Staging can have a bearing on the best treatment modality for femoral AVN. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Radiologic progression is dependent on age at initial involvement. Plain radiographs may be remarkable for flattening of the femoral head, whereas MRI shows an abnormally bright signal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87276 \" href=\"UTD.htm?30/60/31686\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/86\">",
"     86",
"    </a>",
"    ]. The immature epiphysis can undergo remodeling despite initial necrosis and subsequent flattening of the femoral head. However, AVN of the mature femoral head leads to collapse, resulting in persistent degenerative changes and pain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107811872\">",
"    <span class=\"h2\">",
"     Other joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are case reports of AVN affecting other joints and bony structures, including the mandibular condyle and temporomandibular joint [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/88\">",
"     88",
"    </a>",
"    ] and the elbow [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/89\">",
"     89",
"    </a>",
"    ], though the incidence and prevalence of involvement of these sites is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of osteonecrosis in patients with SCD is challenging. The most difficult treatment decision with AVN of the hip is whether to manage conservatively or with surgery. Conservative measures, such as non-weight bearing with crutches, bed rest, and early transfusion have been advocated for early management of AVN, but the success rate is low [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. In general, we prefer to try conservative measures first.",
"   </p>",
"   <p>",
"    Surgical treatment is an option for those who are not helped by conservative measures, but it is not as effective in patients with SCD as it is in those without SCD. In one systematic review, arthroplasty for SCD-associated hip osteonecrosis had a failure rate of 32 percent, significantly higher than for hip disease of other etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/94\">",
"     94",
"    </a>",
"    ], although a small case series of six patients followed for a median of four years suggests better outcomes in patients younger than 21 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/95\">",
"     95",
"    </a>",
"    ]. The procedure is also associated with a relatively high post-operative morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/96\">",
"     96",
"    </a>",
"    ], though this may be improving with better perioperative care.",
"   </p>",
"   <p>",
"    The role of core decompression procedures in arresting or delaying progressive joint damage is controversial. One case-control series found a benefit to core decompression in prolonging the interval to arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/97\">",
"     97",
"    </a>",
"    ], while a systematic review of core-decompression for femoral osteonecrosis of all etiologies found utility to this therapy predominantly in early cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/98\">",
"     98",
"    </a>",
"    ]. However, in one small randomized study of patients with SCD, physical therapy alone appeared to be as effective as hip core decompression followed by physical therapy in improving hip function and postponing the need for additional surgical intervention at a mean of three years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/99\">",
"     99",
"    </a>",
"    ]. A Cochrane Database systematic review revealed no evidence that adding surgical decompression to physical therapy results in clinical improvement in SCD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These apparently contradictory studies suggest that the pathophysiology and natural history of femoral AVN in SCD are different from osteonecrosis in individuals without SCD. Reduced weight-bearing, mobilization with crutches or a wheelchair, and sustained physical therapy to maintain range of motion in the hip, strengthen the hip muscles, and provide gait training [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/99\">",
"     99",
"    </a>",
"    ] may be the preferred therapeutic option for most patients, with core decompression procedures reserved for those who are clearly failing this therapy. Concomitant humeral head AVN may limit the ability of a patient with femoral head AVN to use crutches or a wheelchair.",
"   </p>",
"   <p>",
"    Principles for management of AVN of the humeral head are similar to those of the hip, with conservative medical care and physical therapy used as first line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER BONY ABNORMALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Orbital bone infarction and orbital compression syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bony infarcts can occur in unusual locations, including the walls of the orbits. Orbital infarction is characterized by acute periorbital pain and swelling, and can be accompanied by the formation of subperiosteal or intracranial hematomas. Inflammation associated with infarction of the bone, within the limited bony space of the orbit, can result in an orbital compression syndrome characterized by proptosis, limitation of extraocular movement, corneal hyperesthesia, and optic nerve dysfunction. This condition can be mistaken for orbital cellulitis, but it will not respond to antibiotic therapy. Conservative medical therapy is adequate for orbital bone infarction in the absence of neurological symptoms, but significant hematomas or optic nerve compromise necessitate urgent surgical drainage of the hematoma for resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/101\">",
"     101",
"    </a>",
"    ]. Bone infarctions in other sites of the face and skull have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/27,102-106\">",
"     27,102-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6833543\">",
"    <span class=\"h2\">",
"     Vertebral anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vertebrae in patients with sickle cell disease are prone to changes induced by bone marrow hyperplasia, osteopenia, vaso-occlusive crisis, and avascular necrosis. A cohort study of 34 young patients with SCD revealed structural changes due to bone marrow hyperplasia in 44 percent, and AVN with collapse of the vertebral bodies in 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/107\">",
"     107",
"    </a>",
"    ]. Patients with SCD are also prone to decreased bone mineral density in the lumbar spine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/108\">",
"     108",
"    </a>",
"    ]. Vertebral bodies in these patients often have characteristic findings, including \"tower vertebrae\" (ie, vertebrae with compensatory elongation located next to infarcted short vertebrae [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/109\">",
"     109",
"    </a>",
"    ]) and \"fish vertebrae\" (biconcave vertebral bodies formed by ischemia of the central growth plate of the vertebral body [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/110\">",
"     110",
"    </a>",
"    ]). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Reduced bone mineralization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Abnormal growth and development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cooperative Study of SCD evaluated the impact of sickle hemoglobinopathies on growth and development [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/111\">",
"     111",
"    </a>",
"    ]. Children with HbSS or HbS-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia were found to be significantly smaller than age-related healthy African-American children, although differences in height were less pronounced than were discrepancies in weight and sexual development. In a small study of 41 children, patients with the",
"    <span class=\"nowrap\">",
"     CAR/CAR",
"    </span>",
"    (Central African Republic or Bantu) haplotype had significantly lower growth velocities than did those with the",
"    <span class=\"nowrap\">",
"     Ben/Ben",
"    </span>",
"    haplotype (Benin, the most common haplotype found in the United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/112\">",
"     112",
"    </a>",
"    ]. Levels of growth hormone and insulin-like growth factor 1 (IGF-1), as well as IGF binding protein-3 (IGFBP-3), were lower in patients with the",
"    <span class=\"nowrap\">",
"     CAR/CAR",
"    </span>",
"    haplotype, and positively correlated with hematocrit and level of fetal hemoglobin.",
"   </p>",
"   <p>",
"    The exact mechanisms by which SCD results in impaired growth are unclear, but are likely multifactorial and include chronic anemia and systemic inflammation, episodic acute illnesses, endocrine dysfunction, and micronutrient deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Baseline IGF-1 levels and response to growth hormone stimulation are defective in a significant proportion of prepubertal children with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/115\">",
"     115",
"    </a>",
"    ], and approximately 24 percent of men with SCD appear to have some component of central hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/116\">",
"     116",
"    </a>",
"    ], suggesting that sickle cell disease is associated with both central and peripheral endocrine dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Reduced bone mineralization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 90 pediatric patients with HbSS by dual-energy x-ray absorptiometry demonstrated lower bone mineral content in patients with HbSS compared with control patients adjusted for age, height, pubertal status, and lean mass [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/117\">",
"     117",
"    </a>",
"    ]. Bone mineral content is also reduced in a high percentage of adults with sickle cell disease, with predilection for the lumbar spine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/108,118\">",
"     108,118",
"    </a>",
"    ]. Vitamin D deficiency is a common finding among pediatric and adult patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/117,119\">",
"     117,119",
"    </a>",
"    ]. Although one study suggests no correlation between low bone mineral density and vitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/120\">",
"     120",
"    </a>",
"    ], another finds a correlation between lower levels of plasma vitamin D and more frequent and severe bone disease in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/121\">",
"     121",
"    </a>",
"    ]. Treatment of SCD patients with vitamin D and calcium supplementation can improve bone mineral density, but does not affect markers of bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?18/4/18506/abstract/122\">",
"     122",
"    </a>",
"    ]. It remains to be determined by prospective randomized controlled trials whether therapy with supplemental vitamin D and calcium can help prevent or reduce the incidence of chronic bone disease, including osteopenia, osteoporosis, and avascular necrosis, in patients with SCD.",
"   </p>",
"   <p>",
"    The uses of vitamin D to correct vitamin deficiencies and to treat chronic pain in patients with SCD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H30509050#H30509050\">",
"     \"Overview of the management of sickle cell disease\", section on 'Nutrition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the management of sickle cell disease\", section on 'Chronic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21708512\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with sickle cell disease have a high incidence of acute and chronic disorders of bones and joints, including vaso-occlusive pain crises, osteomyelitis and septic arthritis, osteonecrosis of the femoral and humeral heads, vertebral body collapse, decreased growth, and decreased bone mineral density.",
"     </li>",
"     <li>",
"      Repeated painful vaso-occlusive crises (VOCs) are the hallmark of sickle cell disease (SCD). VOCs lead to infarcts, necrosis, and degenerative changes in bone marrow-containing bone. Long bones are affected most commonly, but VOC can affect any bone marrow-containing structure, including the ribs, sternum, vertebral bodies, and skull. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The differentiation between VOC and osteomyelitis can be difficult. VOC is much more common than osteomyelitis, usually responds within a few days to aggressive pain management, and typically presents in an otherwise well child with little or no fever. In patients with VOC, plain radiographs initially do not show abnormalities but may display increased roentgenographic density within one or two weeks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of VOCs consists of hydration, warm packs to the affected area(s), and a combination of analgesic and anti-inflammatory medications. Early intervention at home can often prevent escalation of the crisis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Key elements of inpatient management include prompt and effective treatment of pain (usually with intravenous opioids), hydration, incentive spirometry, and ambulation if possible to reduce risks for acute chest syndrome.",
"     </li>",
"     <li>",
"      For patients with HbSS or HbS-beta",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia and repeated episodes of VOC, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      (HU) can decrease the frequency of painful episodes. Preliminary studies suggest benefit for patients with HbSC as well. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hydroxyurea'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"       \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dactylitis (hand-foot syndrome) refers to VOC occurring in the small bones of the hand and feet. It typically occurs in infants and young children with SCD, and presents as painful swelling of the hands or feet, often accompanied by mild erythema and low-grade fever. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dactylitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SCD are at risk for osteomyelitis and septic arthritis because of decreased splenic function and changes in bone structure. The clinical presentation is often similar to a VOC, except that swelling and pain are more likely to be in a single site, and fever and pain are more likely to be prolonged. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Osteomyelitis and septic arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteonecrosis (avascular necrosis, AVN) of the femoral or humeral heads occurs in approximately 10 percent of individuals with SCD, and its prevalence increases with age. It may be asymptomatic or present with pain upon weight-bearing. Optimal treatment has not been established; options include pain management and decreased weight bearing, physical therapy, and surgical core decompression. Early detection and intervention may be of value in preventing or delaying progressive joint disease. Arthroplasty is generally delayed as long as possible given the high rate of artificial joint failure in SCD patients. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Osteonecrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SCD have a disproportionate prevalence of low bone mineral density, possibly associated with a concurrent prevalence of vitamin D deficiency. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Reduced bone mineralization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H30509050#H30509050\">",
"       \"Overview of the management of sickle cell disease\", section on 'Nutrition'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6832540\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Brigitta U Mueller, MD, MHCM, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/1\">",
"      Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/2\">",
"      Platt OS. Easing the suffering caused by sickle cell disease. N Engl J Med 1994; 330:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/3\">",
"      Almeida A, Roberts I. Bone involvement in sickle cell disease. Br J Haematol 2005; 129:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/4\">",
"      Ware MA, Hambleton I, Ochaya I, Serjeant GR. Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? Br J Haematol 1999; 104:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/5\">",
"      Darbari DS, Onyekwere O, Nouraie M, et al. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr 2012; 160:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/6\">",
"      Hebbel RP, Vercellotti G, Nath KA. A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis. Cardiovasc Hematol Disord Drug Targets 2009; 9:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/7\">",
"      Michaels LA, Ohene-Frempong K, Zhao H, Douglas SD. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 1998; 92:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/8\">",
"      Mollapour E, Porter JB, Kaczmarski R, et al. Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease. Blood 1998; 91:3423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/9\">",
"      Barbeau P, Woods KF, Ramsey LT, et al. Exercise in sickle cell anemia: effect on inflammatory and vasoactive mediators. Endothelium 2001; 8:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/10\">",
"      Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000; 22:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/11\">",
"      Browne PV, Mosher DF, Steinberg MH, Hebbel RP. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996; 51:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/12\">",
"      Brittain HA, Eckman JR, Swerlick RA, et al. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993; 81:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/13\">",
"      Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 2002; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/14\">",
"      Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005; 19:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/15\">",
"      Serjeant GR, Ceulaer CD, Lethbridge R, et al. The painful crisis of homozygous sickle cell disease: clinical features. Br J Haematol 1994; 87:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/16\">",
"      Belcher JD, Marker PH, Weber JP, et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000; 96:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/17\">",
"      Graido-Gonzalez E, Doherty JC, Bergreen EW, et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 1998; 92:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/18\">",
"      Wagener FA, Abraham NG, van Kooyk Y, et al. Heme-induced cell adhesion in the pathogenesis of sickle-cell disease and inflammation. Trends Pharmacol Sci 2001; 22:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/19\">",
"      Patel RP. Biochemical aspects of the reaction of hemoglobin and NO: implications for Hb-based blood substitutes. Free Radic Biol Med 2000; 28:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/20\">",
"      Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/21\">",
"      Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med 2008; 44:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/22\">",
"      Gelfand MJ, Daya SA, Rucknagel DL, et al. Simultaneous occurrence of rib infarction and pulmonary infiltrates in sickle cell disease patients with acute chest syndrome. J Nucl Med 1993; 34:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/23\">",
"      Roger E, Letts M. Sickle cell disease of the spine in children. Can J Surg 1999; 42:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/24\">",
"      Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia-- imaging a shared neuronal network. Science 2002; 295:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/25\">",
"      Berger E, Saunders N, Wang L, Friedman JN. Sickle cell disease in children: differentiating osteomyelitis from vaso-occlusive crisis. Arch Pediatr Adolesc Med 2009; 163:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/26\">",
"      Keeley K, Buchanan GR. Acute infarction of long bones in children with sickle cell anemia. J Pediatr 1982; 101:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/27\">",
"      Resar LM, Oliva MM, Casella JF. Skull infarction and epidural hematomas in a patient with sickle cell anemia. J Pediatr Hematol Oncol 1996; 18:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/28\">",
"      Rao SP, Miller S, Solomon N. Acute bone and joint manifestations of sickle cell disease in children. N Y State J Med 1986; 86:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/29\">",
"      Alavi A, Heyman S, Kim HC. Scintigraphic examination of bone and marrow infarcts in sickle cell disorders. Semin Roentgenol 1987; 22:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/30\">",
"      Rao S, Solomon N, Miller S, Dunn E. Scintigraphic differentiation of bone infarction from osteomyelitis in children with sickle cell disease. J Pediatr 1985; 107:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/31\">",
"      Skaggs DL, Kim SK, Greene NW, et al. Differentiation between bone infarction and acute osteomyelitis in children with sickle-cell disease with use of sequential radionuclide bone-marrow and bone scans. J Bone Joint Surg Am 2001; 83-A:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/32\">",
"      Mankad VN, Williams JP, Harpen MD, et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. Blood 1990; 75:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/33\">",
"      Shapiro BS, Dinges DF, Orne EC, et al. Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance. Pain 1995; 61:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/34\">",
"      Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics 2002; 109:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/35\">",
"      Jacob E, American Pain Society. Pain management in sickle cell disease. Pain Manag Nurs 2001; 2:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/36\">",
"      Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000; 95:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/37\">",
"      Jacob E, Miaskowski C, Savedra M, et al. Changes in intensity, location, and quality of vaso-occlusive pain in children with sickle cell disease. Pain 2003; 102:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/38\">",
"      van Beers EJ, van Tuijn CF, Nieuwkerk PT, et al. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol 2007; 82:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/39\">",
"      Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/40\">",
"      Sobota A, Graham DA, Neufeld EJ, Heeney MM. Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation. Pediatr Blood Cancer 2012; 58:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/41\">",
"      Leschke J, Panepinto JA, Nimmer M, et al. Outpatient follow-up and rehospitalizations for sickle cell disease patients. Pediatr Blood Cancer 2012; 58:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/42\">",
"      Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/43\">",
"      Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996; 128:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/44\">",
"      Gibbs WJ, Hagemann TM. Purified poloxamer 188 for sickle cell vaso-occlusive crisis. Ann Pharmacother 2004; 38:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/45\">",
"      Kutlar A, Ataga KI, McMahon L, et al. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol 2012; 87:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/46\">",
"      Luo W, Campbell A, Wang H, et al. P-selectin glycoprotein ligand-1 inhibition blocks increased leukocyte-endothelial interactions associated with sickle cell disease in mice. Blood 2012; 120:3862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/47\">",
"      Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/48\">",
"      Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/49\">",
"      Pegelow CH. Survey of pain management therapy provided for children with sickle cell disease. Clin Pediatr (Phila) 1992; 31:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/50\">",
"      Darbari DS, Castro O, Taylor JG 6th, et al. Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc 2008; 100:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/51\">",
"      Vandy Black L, Smith WR. Evidence-based mini-review: Are systemic corticosteroids an effective treatment for acute pain in sickle cell disease? Hematology Am Soc Hematol Educ Program 2010; 2010:416.",
"     </a>",
"    </li>",
"    <li>",
"     NHLBI 2002 Guidelines. file://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf (Accessed on February 05, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/53\">",
"      Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr 1994; 125:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/54\">",
"      Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995; 86:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/55\">",
"      Stevens MC, Padwick M, Serjeant GR. Observations on the natural history of dactylitis in homozygous sickle cell disease. Clin Pediatr (Phila) 1981; 20:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/56\">",
"      Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/57\">",
"      Bennett OM. Salmonella osteomyelitis and the hand-foot syndrome in sickle cell disease. J Pediatr Orthop 1992; 12:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/58\">",
"      Webb DK, Serjeant GR. Haemophilus influenzae osteomyelitis complicating dactylitis in homozygous sickle cell disease. Eur J Pediatr 1990; 149:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/59\">",
"      Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/60\">",
"      Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012; 120:4304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/61\">",
"      Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) 1971; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/62\">",
"      Bennett OM, Namnyak SS. Bone and joint manifestations of sickle cell anaemia. J Bone Joint Surg Br 1990; 72:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/63\">",
"      Anand AJ, Glatt AE. Salmonella osteomyelitis and arthritis in sickle cell disease. Semin Arthritis Rheum 1994; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/64\">",
"      Neonato MG, Lu CY, Guilloud-Bataille M, et al. Genetic polymorphism of the mannose-binding protein gene in children with sickle cell disease: identification of three new variant alleles and relationship to infections. Eur J Hum Genet 1999; 7:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/65\">",
"      Tamouza R, Neonato MG, Busson M, et al. Infectious complications in sickle cell disease are influenced by HLA class II alleles. Hum Immunol 2002; 63:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/66\">",
"      Chambers JB, Forsythe DA, Bertrand SL, et al. Retrospective review of osteoarticular infections in a pediatric sickle cell age group. J Pediatr Orthop 2000; 20:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/67\">",
"      Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics 1998; 101:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/68\">",
"      HOOK EW, CAMPBELL CG, WEENS HS, COOPER GR. Salmonella osteomyelitis in patients with sickle-cell anemia. N Engl J Med 1957; 257:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/69\">",
"      Syrogiannopoulos GA, McCracken GH Jr, Nelson JD. Osteoarticular infections in children with sickle cell disease. Pediatrics 1986; 78:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/70\">",
"      Sadat-Ali M. The status of acute osteomyelitis in sickle cell disease. A 15-year review. Int Surg 1998; 83:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/71\">",
"      Thanni LO. Bacterial osteomyelitis in major sickling haemoglobinopathies: geographic difference in pathogen prevalence. Afr Health Sci 2006; 6:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/72\">",
"      Sankaran-Kutty M, Sadat-Ali M, Kutty MK. Septic arthritis in sickle cell disease. Int Orthop 1988; 12:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/73\">",
"      Nistala K, Murray KJ. Co-existent sickle cell disease and juvenile rheumatoid arthritis. Two cases with delayed diagnosis and severe destructive arthropathy. J Rheumatol 2001; 28:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/74\">",
"      Umans H, Haramati N, Flusser G. The diagnostic role of gadolinium enhanced MRI in distinguishing between acute medullary bone infarct and osteomyelitis. Magn Reson Imaging 2000; 18:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/75\">",
"      William RR, Hussein SS, Jeans WD, et al. A prospective study of soft-tissue ultrasonography in sickle cell disease patients with suspected osteomyelitis. Clin Radiol 2000; 55:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/76\">",
"      Rao VM, Mitchell DG, Rifkin MD, et al. Marrow infarction in sickle cell anemia: correlation with marrow type and distribution by MRI. Magn Reson Imaging 1989; 7:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/77\">",
"      Booz MM, Hariharan V, Aradi AJ, Malki AA. The value of ultrasound and aspiration in differentiating vaso-occlusive crisis and osteomyelitis in sickle cell disease patients. Clin Radiol 1999; 54:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/78\">",
"      Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991; 325:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/79\">",
"      Hawker H, Neilson H, Hayes RJ, Serjeant GR. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease. Br J Haematol 1982; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/80\">",
"      Adekile AD, Gupta R, Yacoub F, et al. Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of alpha-thalassemia trait. Acta Haematol 2001; 105:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/81\">",
"      Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res 1993; :136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/82\">",
"      Poignard A, Flouzat-Lachaniette CH, Amzallag J, et al. The natural progression of symptomatic humeral head osteonecrosis in adults with sickle cell disease. J Bone Joint Surg Am 2012; 94:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/83\">",
"      Hernigou P, Galacteros F, Bachir D, Goutallier D. Deformities of the hip in adults who have sickle-cell disease and had avascular necrosis in childhood. A natural history of fifty-two patients. J Bone Joint Surg Am 1991; 73:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/84\">",
"      Hernigou P, Habibi A, Bachir D, Galacteros F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am 2006; 88:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/85\">",
"      Mont MA, Marulanda GA, Jones LC, et al. Systematic analysis of classification systems for osteonecrosis of the femoral head. J Bone Joint Surg Am 2006; 88 Suppl 3:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/86\">",
"      Mitchell DG, Steinberg ME, Dalinka MK, et al. Magnetic resonance imaging of the ischemic hip. Alterations within the osteonecrotic, viable, and reactive zones. Clin Orthop Relat Res 1989; :60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/87\">",
"      Huo MH, Friedlaender GE, Marsh JS. Orthopaedic manifestations of sickle-cell disease. Yale J Biol Med 1990; 63:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/88\">",
"      Baykul T, Aydin MA, Nasir S. Avascular necrosis of the mandibular condyle causing fibrous ankylosis of the temporomandibular joint in sickle cell anemia. J Craniofac Surg 2004; 15:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/89\">",
"      Mukisi Mukaza M, Manicom O, Fillipini P, Hernigou P. Elbow osteonecrosis in sickle cells anemia: a study of six cases. Orthop Traumatol Surg Res 2009; 95:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/90\">",
"      Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/91\">",
"      Steinberg ME. Early diagnosis of avascular necrosis of the femoral head. Instr Course Lect 1988; 37:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/92\">",
"      Garino JP, Steinberg ME. Total hip arthroplasty in patients with avascular necrosis of the femoral head: a 2- to 10-year follow-up. Clin Orthop Relat Res 1997; :108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/93\">",
"      Steinberg ME. Classification of avascular necrosis: a comparative study. Acta Orthop Belg 1999; 65 Suppl 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/94\">",
"      Johannson HR, Zywiel MG, Marker DR, et al. Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty: a systematic literature review. Int Orthop 2011; 35:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/95\">",
"      Kamath AF, Sheth NP, Hosalkar HH, et al. Modern total hip arthroplasty in patients younger than 21 years. J Arthroplasty 2012; 27:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/96\">",
"      Vichinsky EP, Neumayr LD, Haberkern C, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. Am J Hematol 1999; 62:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/97\">",
"      Mukisi-Mukaza M, Manicom O, Alexis C, et al. Treatment of sickle cell disease's hip necrosis by core decompression: a prospective case-control study. Orthop Traumatol Surg Res 2009; 95:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/98\">",
"      Marker DR, Seyler TM, McGrath MS, et al. Treatment of early stage osteonecrosis of the femoral head. J Bone Joint Surg Am 2008; 90 Suppl 4:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/99\">",
"      Neumayr LD, Aguilar C, Earles AN, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am 2006; 88:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/100\">",
"      Mart&iacute;-Carvajal AJ, Sol&agrave; I, Agreda-P&eacute;rez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev 2012; 5:CD004344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/101\">",
"      Saito N, Nadgir RN, Flower EN, Sakai O. Clinical and radiologic manifestations of sickle cell disease in the head and neck. Radiographics 2010; 30:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/102\">",
"      Curran EL, Fleming JC, Rice K, Wang WC. Orbital compression syndrome in sickle cell disease. Ophthalmology 1997; 104:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/103\">",
"      Ganesh A, William RR, Mitra S, et al. Orbital involvement in sickle cell disease: a report of five cases and review literature. Eye (Lond) 2001; 15:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/104\">",
"      Naran AD, Fontana L. Sickle cell disease with orbital infarction and epidural hematoma. Pediatr Radiol 2001; 31:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/105\">",
"      Royal JE, Harris VJ, Sansi PK. Facial bone infarcts in sickle cell syndromes. Radiology 1988; 169:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/106\">",
"      Ganesh A, Al-Zuhaibi S, Pathare A, et al. Orbital infarction in sickle cell disease. Am J Ophthalmol 2008; 146:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/107\">",
"      Sadat-Ali M, Ammar A, Corea JR, Ibrahim AW. The spine in sickle cell disease. Int Orthop 1994; 18:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/108\">",
"      Sarrai M, Duroseau H, D'Augustine J, et al. Bone mass density in adults with sickle cell disease. Br J Haematol 2007; 136:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/109\">",
"      Marlow TJ, Brunson CY, Jackson S, Schabel SI. \"Tower vertebra\": a new observation in sickle cell disease. Skeletal Radiol 1998; 27:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/110\">",
"      Westerman MP, Greenfield GB, Wong PW. \"Fish vertebrae,\" homocystinuria, and sickle cell anemia. JAMA 1974; 230:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/111\">",
"      Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med 1984; 311:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/112\">",
"      Luporini SM, Bendit I, Manhani R, et al. Growth hormone and insulin-like growth factor I axis and growth of children with different sickle cell anemia haplotypes. J Pediatr Hematol Oncol 2001; 23:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/113\">",
"      Bennett EL. Understanding growth failure in children with homozygous sickle-cell disease. J Pediatr Oncol Nurs 2011; 28:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/114\">",
"      Al-Saqladi AW, Cipolotti R, Fijnvandraat K, Brabin BJ. Growth and nutritional status of children with homozygous sickle cell disease. Ann Trop Paediatr 2008; 28:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/115\">",
"      Soliman AT, Bererhi H, Darwish A, et al. Decreased bone mineral density in prepubertal children with sickle cell disease: correlation with growth parameters, degree of siderosis and secretion of growth factors. J Trop Pediatr 1998; 44:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/116\">",
"      Taddesse A, Woldie IL, Khana P, et al. Hypogonadism in patients with sickle cell disease: central or peripheral? Acta Haematol 2012; 128:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/117\">",
"      Buison AM, Kawchak DA, Schall JI, et al. Bone area and bone mineral content deficits in children with sickle cell disease. Pediatrics 2005; 116:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/118\">",
"      Sadat-Ali M, Al-Elq AH, Sultan O, et al. Low bone mass due to sickle cell anemia: is it becoming a real issue? West Afr J Med 2008; 27:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/119\">",
"      Goodman BM 3rd, Artz N, Radford B, Chen IA. Prevalence of vitamin D deficiency in adults with sickle cell disease. J Natl Med Assoc 2010; 102:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/120\">",
"      Chapelon E, Garabedian M, Brousse V, et al. Osteopenia and vitamin D deficiency in children with sickle cell disease. Eur J Haematol 2009; 83:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/121\">",
"      Arlet JB, Courbebaisse M, Chatellier G, et al. Relationship between vitamin D deficiency and bone fragility in sickle cell disease: a cohort study of 56 adults. Bone 2013; 52:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/4/18506/abstract/122\">",
"      Adewoye AH, Chen TC, Ma Q, et al. Sickle cell bone disease: response to vitamin D and calcium. Am J Hematol 2008; 83:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5919 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18506=[""].join("\n");
var outline_f18_4_18506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21708512\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VASO-OCCLUSIVE CRISES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107811541\">",
"      - Pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6833306\">",
"      - Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DACTYLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OSTEOMYELITIS AND SEPTIC ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OSTEONECROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22080169\">",
"      Humeral head",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22080134\">",
"      Femoral head",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107812031\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107812038\">",
"      - Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107811872\">",
"      Other joints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER BONY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Orbital bone infarction and orbital compression syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6833543\">",
"      Vertebral anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Abnormal growth and development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Reduced bone mineralization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21708512\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6832540\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/5919\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5919|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/2/27682\" title=\"diagnostic image 1A\">",
"      Red marrow normal adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/3/26675\" title=\"diagnostic image 1B\">",
"      Red marrow sickle cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/51/13104\" title=\"diagnostic image 2\">",
"      Vert collapse sickle cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/4/11342\" title=\"diagnostic image 3\">",
"      MRI wrist septic arthritis child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/60/31686\" title=\"diagnostic image 4\">",
"      Avascular necrosis of femoral heads in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5919|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/51/41790\" title=\"figure 1\">",
"      Predictors of adverse outcome sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39961?source=related_link\">",
"      Management of fever in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_4_18507="Types of laparoscopic hyst 2";
var content_f18_4_18507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Diagnostic laparoscopy with vaginal hysterectomy (VH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopic vault suspension after vaginal hysterectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopic assisted vaginal hysterectomy (LAVH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopic hysterectomy (LH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total laparoscopic hysterectomy (TLH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopic supracervical hysterectomy (LSH) or Classic abdominal SEMM hysterectomy (CASH), where SEMM stands for Serrated Edge Macro Morcellator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopic hysterectomy with lymphadenectomy (LHL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopic hysterectomy with lymphadenectomy and omentectomy (LHL+0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radical laparoscopic hysterectomy (RLH), which is usually the combination of a laparoscopic lymphadenectomy combined with a radical Shauta's vaginal hysterectomy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Garry, R, Reich, H. Basic techniques for advanced laparoscopic surgery. In: Laparoscopic Hysterectomy, Garry, R, Reich, H (Eds), Blackwell Scientific, Oxford 1992. p. 46.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18507=[""].join("\n");
var outline_f18_4_18507=null;
var title_f18_4_18508="Complications refractive surg";
var content_f18_4_18508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of laser refractive surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            PRK/LASIK/LASEK",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Overcorrection/undercorrection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Astigmatism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Regression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glare, halo, monocular diplopia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dry eye symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reduced contrast sensitivity",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            More common in PRK",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postoperative pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Delayed epithelial healing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scarring/stromal haze",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            More common in LASIK",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Flap complications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epithelial ingrowth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diffuse lamellar keratitis (Sands of Sahara)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            More common in LASEK",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postoperative pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stromal haze",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Flap complications",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PRK: photorefractive keratectomy; LASIK: laser-assisted in situ keratomileusis; LASEK: laser epithelial keratomileusis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18508=[""].join("\n");
var outline_f18_4_18508=null;
var title_f18_4_18509="Incidence of sudden death in men and women increases with age";
var content_f18_4_18509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incidence of sudden death in men and women increases with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a 38-year follow-up of subjects in the Framingham Heart Study, the annual incidence of sudden death increased with age in both men and women. However, at each age, the incidence of sudden death is higher in men than women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kannel WB, Wilson PWF, D'Agostino RB, et al. Am Heart J 1998; 136:205.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18509=[""].join("\n");
var outline_f18_4_18509=null;
var title_f18_4_18510="Polyclonal pattern on SPEP";
var content_f18_4_18510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polyclonal gammopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Densitometer tracing of these findings reveals a broad-based peak of gamma mobility. This pattern is most often due to the presence of an inflammatory or reactive process, such as chronic liver disease, connective tissue disease, chronic infection, or a lymphoproliferative disorder.",
"    <br>",
"     (B) A polyclonal pattern is seen on serum protein electrophoresis on agarose gel (anode on left). The band at the right (red asterisk) is broad, and extends throughout the gamma mobility area.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Kyle RA, Rajkumar SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman L, Ausiello DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright &copy; 2004 Elsevier.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18510=[""].join("\n");
var outline_f18_4_18510=null;
var title_f18_4_18511="Metastatic chordoma CT";
var content_f18_4_18511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metastatic chordoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan showing multiple nodules secondary to metastases from a sacral chordoma. The lesions are round, smooth bordered, and peripherally located.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_4_18511=[""].join("\n");
var outline_f18_4_18511=null;
